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1. INTRODUCTION
1.1 Oral drug delivery
Drugs are most frequently administered by oral route. Although a few drugs
taken orally are intended to be dissolved in the mouth, nearly all drugs taken orally
are swallowed. Of these, most are taken for the systemic drugs effects that result
after absorption from the various surfaces along the gastrointestinal tracts. A few
drugs such as antacids are swallowed for their local action in the gastrointestinal
tracts.1
Oral drug delivery is the most widely utilized route of administration among
all the routes that have been explored for systemic delivery of drugs via
pharmaceutical products of different dosage form. Oral route is considered most
natural, uncomplicated, convenient and safe due to its ease of administration, patient
acceptance, cost-effective manufacturing process and flexibility in dosage form.7
Oral sustained release dosage forms have been developed and studied to restrict
these systems to specific regions of the gastrointestinal tract as well as to improve
the pharmacological activity and to reduce toxic effects.8 The majority of oral
sustained release systems rely on dissolution, diffusion or a combination of both
mechanisms, to generate slow release of drug to the gastrointestinal milieu.9
1.2 Historical perspective of sustained drug delivery
Probably the earliest work in the area of sustained drug delivery dosage
forms can be traced from 1938 patent of Israel Lipowski. This work involved coated
pellets for prolong release of drug and was presumably the forerunner to the
development of the coated particle approach to sustained drug delivery that was
introduced in the early 1950’s. There has been 40 years of research and development
experience in the sustained release area since that patent, and a number of strategies
have been developed to prolong drug levels in the body. These range from the very
simple, slowly dissolving pellets or tablets to the technologically sophisticated
controlled drug-release systems which have been recently started to appear in the
market and in pharmaceutical literature.20
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Over past 30 years, as the expense and complications involved in marketing
new drug entities have increased, with concomitant recognition of therapeutic
advantages of controlled drug delivery, greater attention has been focused on
development of sustained or controlled-release drug-delivery systems. There are
several reasons for the attractiveness of these dosage forms. It is generally
recognized that for many disease state, a substantial number of therapeutically
effective compounds already exists. The effectiveness of drug however is often
limited by side effects or the necessity to administer the compounds in clinical
setting.3
Successful fabrication of sustained release products is usually difficult & and
involves consideration of physicochemical properties of drug, pharmacokinetic
behavior of drug, route of administration, disease state to be treated and, most
importantly, placement of the drug in dosage form total will provide the desired
temporal and spatial delivery pattern for the drug.3
The reasons behind the increase in the interest in new system are firstly
reorganization of the possibility of repeating successful drugs by applying the
concepts and techniques of controlled release drug delivery systems, coupled with
the increasing expense in bringing new drug entities to market, has encouraged the
development of new delivery system and secondly new systems are needed to
deliver the novel, genetically engineered pharmaceuticals for example- peptides &
proteins to their site of action without incurring significant immunogenicity or
biological inactivation.3
1.3 Sustained Release Concept3
A sustained release product may be considered one in which a drug is initially
made available to the body in an amount sufficient to cause the desired
pharmacological response as rapidly as is consistent with the properties of the drug
determining its intrinsic availability for absorption; and one which provides for
maintenance of activity at the initial level for a desirable number of hours in excess
of the activity resulting from the usual single dose of drug.5
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For the pharmaceutical industry sustained release dosage forms provide
multiple commercial benefits. Reduced dosing frequency improves patient
compliance. Better therapeutic outcomes due to improved efficacy and improved
tolerability can lead to fewer medication switches and greater physician loyalty.53
For any drug therapy to be successful, the drug must reach the target tissue or
systemic circulation in optimum concentration which should be maintained for
desired time. In recent years, attention has been focused on the development of new
drug delivery system rather than invention of new molecules. Because the
development cost for new drug molecule is very high.26 Sustained release, sustained
action, prolonged action, controlled release, extended action, timed release, depot
and repository dosage forms are terms used to identify drug delivery systems that
are designed to achieve prolonged therapeutic effects by continuously releasing
medication over an extended period of time after administration of single dose.
Sustained release and controlled release will represent separate delivery
processes; sustained release constitutes any dosage from that provides medication
over an extended period of time. Controlled release however, denotes that, system is
able to provide same actual therapeutic control, whether this is temporal nature,
spatial nature, or both. In other words, the system attempts to control drug
concentration in target tissue. This correctly suggests that there are sustained-release
systems that cannot be considered as controlled release.
In general, the goal of a sustained release dosage form is to maintain
therapeutic blood level or tissue level of the drug for extended period. This is
usually accomplished by attempting to obtain zero order release from the dosage
form. Zero order release constitutes of the amount of drug in the delivery system (a
constant release rate). Sustained release systems generally do not attain this type of
release and usually try to minis zero order release by providing drug in a slow first
order fashion (concentration-dependent).
Oral ingestion has been the most convenient and commonly employed route
of drug delivery. Indeed, for sustained – release systems, the oral route of
administration has received the most attention with respect to research on
physiological and drug constraints as well as designing and testing of products.
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With most of orally administered drugs targeting is not primary concern, and
it is usually intended for drugs to permeate to the general circulation and perfuse to
other body tissues (the obvious exception being medication intended for local
gastrointestinal tissue treatment), for this reason, most systems employed are of the
sustained-release variety. It is assumed that increasing concentration at the
absorption site will increase the rate of absorption and, therefore, increase
circulating blood levels, which in turn promotes greater concentrations of the drug at
the site of action. If toxicity is not an issue, therapeutic levels can thus be extended.
Theoretically and desirably a sustained release delivery device, should release the
drug by a zero-order process which would result in a blood-level time profile similar
to that after intravenous constant rate infusion.24
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Figure 2, typical drug blood level versus time profiles following oral multiple
dose therapy6.
Figure 3, typical drug-blood level versus time profile for delayed release drug
delivery by repeat action dosage form6.
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An alternative approach is to administer the drug repetitively using a
constant dosing interval, as in multiple-dose therapy. This is shown in Figure 2 for
the oral route. In this case the drug blood level reached and time required to reach
that level depend on the dose and dosing interval. There are several potential
problems inherent in multiple-dose therapy. If the dosing interval is not appropriate
for the biological half-life of the drug, large peaks and valleys in the drug blood
level may result. For example, drug with short half-life requires frequent dosing to
maintain constant therapeutic levels. The drug blood level may not be within the
therapeutic range at sufficiently early times, an important consideration for certain
disease state. Patient noncompliance with the multiple-dosing regimen can result in
failure of this approach.
1.4 Rationale of sustained drug delivery3
The basic rationale for sustained drug delivery is to alter the
pharmacokinetics and pharmacodynamics of pharmacological active moieties by
using novel drug delivery system or by modifying the molecular structure and
physiological parameters inherent in the selected route of administration. It is
desirable that the duration of drug action becomes more a design property of a
sustained dosage form and less or not at all a property of the drug molecules
inherent kinetic properties. Thus optional design of sustained release system
necessitates a thorough understanding of the pharmacokinetics and
pharmacodynamics of the drugs.22 The aim of sustained drug delivery is to optimize
the biopharmaceutic, pharmacokinetic and pharmacodynamic properties of a drug in
such a way that its utility is maximized through reduction in side-effects and cure or
control of disease condition in the shortest possible time by using smallest quantity
of drug, administered by the most suitable route7.
There are certain considerations for the formation of sustained release
formulations: If the active compound has a long half-life (over six hours), it is
sustained on its own. If the pharmacological activity of the active compound is not
related to its blood levels, time releasing than has no purpose. If the absorption of
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the active component involves an active transport, the development of a time-release
product may be problematic. Finally, if the active compound has a short half-life, it
would require a large amount to maintain a prolonged effective dose. In this case, a
broad therapeutic window is necessary to avoid toxicity; otherwise, the risk is
unworthy to take and another mode of administration would be recommended.24
As mentioned earlier, primary objectives of controlled drug delivery are to
ensure safety and to improve efficiency of drugs as well as patient compliance. This
is achieved by better control of plasma drug levels and frequent dosing. For
conventional dosage forms, only the dose (D) and dosing interval (C) can vary and,
for each drug, there exists a therapeutic window of plasma concentration, below
which therapeutic effect is insufficient, and above which toxic side effects are
elicited. This is often defined as the ratio of median lethal dose (LD 50) to median
effective dose (ED50).
1.5 Potential advantages of sustained drug therapy6.
1) Improved patient convenience and compliance due to less frequent drug
dosing.
 Employs minimum drug.
 Minimizes or eliminates local and systemic side effects.
 Obtain less potentiating or deduction in drug activity with chronic
use.
 Avoidance of night time dosing.
2) Reduction in fluctuation in steady-state levels and therefore-
 Better control of disease condition, and
 Reduced intensity of local or systemic side-effects.
 It minimizes drug accumulation with chronic dosing.
3) Improves efficacy in treatment.
 Cure or control confirm more promptly.
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 Improve control of condition thereby reducing fluctuation in
circulating drug level.
 Improve bioavailability of some drugs.
 Make use of special effects, example- sustained release aspect for
morning.
 More uniform effect.
4) Reduction in health care costs through-
 Improved therapy.
 Shorter treatment period.
 Lower frequency of dosing.
 Reduction in personnel time to dispense, administer and monitor
patients.
5) Improved therapy-
 Sustained blood level- The dosage form provides uniform drug
availability/blood levels unlike peak and valley pattern obtained by
intermittent administration.
 Attenuation of adverse effects- The incidence and intensity of
undesirable side effects caused by excessively high peak drug
concentration resulting from the administration of conventional
dosage form is reduced.
 It is seldom that a dose is missed because of non-compliance by the
patient.
6) Increased safety margin of high potency drugs due to better control of
plasma levels.
7) Maximum utilization of drug enabling reduction in total amount of drug
administered.
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1.6 Disadvantages of sustained release dosage forms7.
 They are costly.
 Unpredictable and often poor in-vitro in-vivo correlations, dose
dumping, reduced potential for dosage adjustment and increased
potential first pass clearance.
 Poor systemic availability in general.
 Effective drug release period is influenced and limited by GI
residence time.
1.7 Factors governing the design of sustained/controlled release dosage form6.
A) Drug related Factors
 Molecular size and diffusivity
 Aqueous solubility and pKa.
 Partition coefficient.
 Molecular size.
 Drug stability.
 Protein binding.
B) Biological factors
 Absorption.
 Distribution.
 Metabolism.
 Elimination.
 Elimination half-life.
 Therapeutic Index.
 Dose size.
 Duration of action.
 Plasma concentration response.
 Margin of safety.
 Side effects.
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 Diseased state.
1.7.1 Physicochemical Factors6,7,34.
1) Molecular size and diffusivity
A drug must diffuse through a variety of biological membranes during its
time course in the body. In addition to these, drugs in many sustained release
systems must diffuse through a rate controlling polymer membrane or matrix. The
ability of a drug to diffuse in polymer, is so called diffusivity (diffusion coefficient
D) is a function of its molecular size (or molecular weight). For most polymers it is
possible to relate log D empirically to some function of molecular size as,
Log D = - Sv log V + Kv = - Sm logM + Km
Where, V = molecular volume.
M = molecular weight.
Sv, Sm, Kv, Km = constant.
The value of 'D' thus is related to the size and shape of the cavities as well as
size and shape of drugs. Generally, values of the diffusion coefficient for drugs of
intermediate molecular weight (i.e150 to 400 Daltons), through flexible polymers,
range from 10-6 to 10-9 cm2/sec, with values in the order of 10-8 being most common.
A value of approximately 10-6 is typical for these drugs through water as the
medium.
For drugs with molecular weight greater than 500 Da, their diffusion
coefficients in many polymers are frequently are so small that they are difficult to
quantify, (i.e., less than 10-12 cm2/sec). Thus, high molecular weight drugs and /or
polymeric drugs should be expected to display very slow release kinetics in
extended-release devices using diffusion through polymeric membranes or matrices
as the releasing mechanism.
2) Aqueous solubility and pKa
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Solubility is defined as the amount of material that remains in solution in a
given volume of solvent containing undissolved material. It is the thermodynamic
property of a compound. The fraction of drug absorbed into the portal blood is a
function of the amount of drug in the solution in the G.I tract, i.e. the intrinsic
permeability of the drug.
For a drug to be absorbed, it must dissolve in the aqueous phase surrounding
the site of administration and then partition into the absorbing membrane. The
aqueous solubility of a drug influences its dissolution rate, which in turn establishes
its concentration in solution and, hence, the driving force for diffusion across
membranes. Dissolution rate is related to aqueous solubility as shown by the Noyes-
Whitney equation that, under sink condition, is dc/dt= KDA.Cs
Where,
dc/dt = Dissolution rate
KD = Dissolution rate constant
A      = Total surface area of the drug particles.
Cs      = Aqueous saturation solubility of the drug.
The dissolution rate is constant only if surface areas (A) remain constant,
but, as the initial rate is directly proportional to aqueous solubility (Cs). Therefore,
the aqueous solubility of a drug can be used as a first approximation of its
dissolution rate. Drugs with low aqueous solubility have low dissolution rates and
usually suffer oral bioavailability problems.
The aqueous solubility of weak acids or bases is governed by the pKa of the
compound and pH of the medium.
For weak acids,
St = S0 (1+Ka/ [H+]) = S0 (1+10 pH-pKa)…………. (1)
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Where,
St = Total solubility (both ionized and un-ionized forms) of the weak
acid
S0 = Solubility of the un-ionized form
Ka= Acid dissociation constant
H+= Hydrogen ion concentration of the medium
Equation (1) predicts that the total solubility, St, of a weak acid with a given
pKa can be affected by the pH of the medium.
For a weak base,
St = S0 (1+ [H+]/Ka) = S0 (1+10pKa-pH)……… (2)
Where,
St = Total solubility (both conjugate acid and free base forms) of the
weak base.
S0 = Solubility of the free base form.
Ka = Acid dissociation constant of the conjugate acid
So, total solubility (St), of a weak base with a given pKa can be affected by
the pH of the medium.
Extremes in the aqueous solubility of a drug are undesirable for formulation
into controlled release product. A drug with very low solubility and a slow
dissolution rate will exhibit dissolution-limited absorption and yield an inherently
sustained blood level. Formulation of such a drug into a controlled-release system
may not provide considerable benefits over conventional dosage forms.
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Any system relying upon diffusion of drug through a polymer as the rate-
limiting step in release would be unsuitable for a poorly soluble drug, since the
driving force for diffusion is the concentration of drug in the polymer or solution,
and this concentration would be low. For a drug with very high solubility and a rapid
dissolution rate, it often is quite difficult to decrease its dissolution rate and slow its
absorption. Preparing a slightly soluble form of a drug with normally high solubility
is, however, one possible method for preparing controlled release dosage forms.
pKa- Ionization Constant
The pKa is a measure of the strength of an acid or a base. The pKa allows us
to determine the charge on a drug molecule at any given pH. Drug molecules are
active in only the undissociated state and also unionized molecules cross these
lipoidal membranes much more rapidly than the ionized species.
3) Partition Coefficient
Partition coefficient influences not only the permeation of drug across the
biological membranes but also diffusion across the rate controlling membrane or
matrix.
Between the time when a drug is administered and when it is eliminated
from the body, it must diffuse through a variety of biological membranes that act
primarily as lipid-like barriers. A major criterion in evaluation of the ability of a
drug to penetrate these lipid membranes (i.e, its membrane permeability) in its
apparent oil/water partition coefficient, defined as
K=C0/Cw
Where,
C0 = Equilibrium concentration of all forms of the drug e.g.,
ionized and unionized in an organic phase at equilibrium.
Cw = Equilibrium concentration of all forms in aqueous
phase.
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Drugs with large values of 'K' are very oil-soluble and will partition into
membrane quite readily. The relationship between tissue permeation and partition
coefficient for the drug generally is defined by the Hansch correlation, which
describes a parabolic relationship between the logarithm of the activity of a drug or
its ability to be absorbed and the logarithm of its partition coefficient.
The explanation for this relationship is that the activity of a drug is a
function of its ability to cross membranes and interact with the receptor. The more
effectively a drug crosses membranes, the greater its activity.
There is also an optimum partition coefficient, value below which results in
decreased lipid solubility, and the drug will remain localized in the first aqueous
phase it contacts. Values larger than the optimum result in poorer aqueous solubility
but enhanced lipid solubility, and the drug will not partition out of the lipid
membrane once it gets in. The value of K at which optimum activity is observed is
approximately 1000/1 in n-octanol/water. Drugs with a partition coefficient that is
higher or lower than the optimum are, in general, poorer candidates for formulation
into extended-release dosage forms.
4) Drug stability
One important factor for the loss of drug is through acid hydrolysis and/or
metabolism in the GIT when administered orally. It is possible to significantly
improve the relative bioavailability of a drug that is unstable in GI tract by placing it
in a slowly available controlled release form. For those drugs that are unstable in the
stomach, the most appropriate controlling unit would be one that releases its content
only in the intestine. The release in the case for those drugs that are unstable in the
environment of the intestine, the most appropriate controlling unit in this case would
be one that releases its contents in the vascular space for controlled drug release to
extravascular tissues, but only for those drugs that exhibit a high degree of binding.
Thus, the protein binding nature of a drug plays significant role in its duration of
therapeutic effect. Extensive binding to plasma proteins will be evidenced by a long
half-life of elimination for the drug and such drugs generally do not require a
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controlled–release dosage form. Drugs sometimes may bind to biopolymers in the
GI tract, which could have an influence on controlled-drug delivery.
Pharmacokinetic and Pharmacodynamic Considerations
1.7.2 Biological Properties6.
1) Absorption
It is the process by which a drug proceeds from the site of administration to
the site of measurement within the body. Since the drug cannot be generally
measured directly at the site of action, its concentration is measured at the
alternative site, the plasma. The concentration of drug in plasma also reflects the
concentration of drug at the site of action. The rate of absorption is then measured as
the rate of disappearance of drug in the plasma.m[jain]The rate, extent and
uniformity of absorption of a drug are important factors when considering its
formulation into an extended-release system. The most critical case of oral
administration is Kr<<<Ka. Assuming that the transit time of drug through the
absorptive area of GIT is between 9-12 hours, the maximum absorption half-life
should be 3-4 hours. This corresponds to a minimum absorption rate constant Ka
value of 0.17-0.23/hr necessary for about 80-95% absorption over a 9-12hr transit
time.
For a drug with a very slow rate of absorption (Ka<<0.17/hr), the first order
release rate constant Kr less than 0.17/hr results is unacceptably poor bioavailability
in many patients. Therefore slowly absorbed drug will be difficult to be formulated
into extended release systems where the criterion Kr<<<Ka must be met. If the drug
were erratically absorbed because of variable absorptive surface of GIT, design of
the sustained release product would be more difficult or prohibitive.
2) Distribution
It refers to the reversible transfer of drugs from one location to another
within the body. Distribution occurs at various rates and to various extents. Several
factors determine the distribution pattern of a drug. They include-
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 rate of delivery of a drug to the tissues by the circulation.
 the ability of a drug to pass through tissue membranes.
 the binding affinity of drug to plasma proteins, erythrocytes,
and tissues.
The distribution of a drug into vascular and extra vascular spaces in the body
is an important factor in its overall elimination kinetics. Apparent volume of
distribution and the ratio of drug in tissue to plasma T/P concentration are used to
describe the distribution characteristics of a drug.
For drugs which have apparent volume of distribution higher than real
volume of distribution i.e., drugs which are extensively bound to extra vascular
tissues, the elimination half life is decreased i.e., the drug leaves the body gradually
provided drug elimination rate is limited by the release of drug from tissue binding
sites and that drug is released from the tissues to give concentrations exceeding the
threshold level or within the therapeutic range, one can assume that such drugs are
inherently sustained. The larger the volume of distribution, the more the drug is
concentrated in the tissues compared with the blood. It is the drug in the blood that
is exposed to hepatic or renal clearance, so that when the distribution volume is
large these mechanisms have fewer drugs to work on. By contrast, if the volume of
distribution is small, most of the drug in the body is in the blood and is accessible to
the elimination process.
3) Metabolism
The metabolism of a drug can either inactivate or active drug or convert an
inactive drug to active metabolite. Complex metabolic patterns would make the
sustained release design much more difficult particularly when biological activity is
wholly or partly due to a metabolite.
There are two areas of concern related to metabolism that significantly
restrict sustained release product design. First, if a drug upon chronic administration
is capable of either inducing or inhibiting enzyme synthesis, it will be a poor
candidate for a sustained release product because of the difficulty of maintaining
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uniform blood levels of a drug. Second, if there is a variable blood level of a drug
through either intestinal (or tissue) metabolism or through first pass effect, this also
will make sustained release dosage form difficult, since most of the process are
saturable, the fraction of the drug loss would be dose dependent and that would
result in significant reduction in bioavailability if the drug is slowly released over a
extended period of time.
4) Elimination
The process of elimination mainly comprises of-
 biotransformation or metabolism of the drug primarily by the
liver, and
 renal excretion of both the unchanged drug and its
metabolites.
 Metabolism by the gut, epithelium, lungs, blood, kidneys, and
other organs and tissues, biliary excretion and excretion
through sweat, saliva and breast milk are some of the other
modes of elimination.
5) Elimination Half Life
Half life is the time taken for the amount of drug in the body (or the plasma
concentration) to fall by half and is determined by both clearance (Cl) and volume of
distribution (Vd).
t1/2=0.693.Vd/Cl
Half life is increased by increasing in volume of distribution or a decrease in
clearance, and vice-versa. The larger the volume of distribution the more the drug is
concentrated in the tissues compared with the blood. If the volume of distribution is
small, most of the drug in the body is in the blood and is accelerated to the
elimination process.
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For drugs that follow linear kinetics, the elimination half-life is constant and
does not change with dose or drug concentration. For drugs that follow non-linear
kinetics, the elimination half-life and drug clearance both change with dose or drug
concentration. Drugs with short half-lives (<2hrs) and high dose impose a constraint
on formulation into sustained release systems because of the necessary dose size and
drugs with long half-lives (>8hrs) are inherently sustained. Sustained release
products for drugs with intrinsically long biological half-lives are available. As
expected, little or no therapeutic advantages have been demonstrated in these
products over conventional dosage forms.
6) Therapeutic Index
It is most widely used to measure the margin of safety of a drug.
TI = TD 50 / ED50
Where,
TD50 = median toxic dose
ED50 = median effective dose
For potent drugs, the value of TI is small. Larger the value of TI, safer is the
drug. Drugs with very small value of TI are poor candidates for formulation into
controlled-release product. A drug is considered to be relatively safe if its TI value
exceeds 10.
7) Dose Size
Generally, controlled-release systems will contain greater amount of drug
than a corresponding conventional dosage form. For those drugs requiring large
conventional doses, the volume of the sustained dose may be so large as to be
impractical or unacceptable. The same may be true for drugs that require a large
release rate from the controlled-release system, e.g., drugs with shorter half-life.
8) Duration of Action
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It is the time period for which the blood levels remain above the MEC and
below the MSC levels (or) more specifically within the therapeutic window. Drugs
acting for long duration are unsuitable candidates for formulation into sustained
release forms.
The long duration of action of few drugs is determined by plasma half-life
and the affinity of binding to tissue. Drugs with short plasma half-life but high
binding tissue may remain active for 24 hours. In contrast few drugs which has
relatively shorter duration of action has weaker tissue binding and short plasma half
life. Receptor occupation, tissue binding, half life, metabolism, partition coefficient,
irreversible binding to cells are some parameters which are responsible for long
duration of action of drugs.
9) Plasma concentration-response
Drugs whose pharmacological activity is independent of its concentration are
poor candidates for sustained release systems.
1.8 Classification of Oral sustained release systems7.
1) Continuous release systems
a) Dissolution controlled release systems.
 Matrix type.
 Reservoir type.
b) Diffusion controlled release systems.
 Matrix type.
 Reservoir type.
c) Dissolution and diffusion controlled release systems.
d) Ion exchange resin drug complexes.
e) Slow dissolving salts and complexes.
f) pH dependent formulations.
g) Osmotic pressure controlled systems.
h) Hydrodynamic pressure controlled systems.
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2) Delayed transit and continuous release systems
Altered density systems.
 High density.
 Low density.
 Floating.
 Mucoadhesive systems.
 Size based systems.
3) Delayed release systems
 Intestinal release systems
 Colonic release systems
1.9 Matrix devices6.
Historically, the most popular drug delivery system has been the matrix
because of its low cost and eases of fabrication. Matrix devices consist of drug
dispersed homogenously throughout a polymer matrix. In the model, drug in the
outside layer exposed to the bathing solution is dissolved first and then diffuses out
of the matrix. Methods of altering the kinetics of drug release from the inherent first
order behavior especially to achieve a constant rate of drug release from matrix
devices have involved several factors24.
This process continues with the interface between the bathing solution and
the solid drug moving toward the interior. For this system, rate of dissolution of drug
particles within the matrix must be much faster than the diffusion rate of the
dissolved drug leaving the matrix.
Derivation of the mathematical model to describe this system involves the
following assumptions:
 A pseudo steady state is maintained during drug release.
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 The diameter of the drug particles is less than the average distance of drug
diffusion through the matrix.
 The bathing solution provides sink conditions at all times.
 The diffusion coefficient of drug in the matrix remains constant i.e. no
change occurs in the characteristics of the polymer matrix.
Higuchi has derived the appropriate equation for drug release for this
system-
dM = Codh-(Cs/2) dh ………….... (1)
Where,
dM = Change in the amount of drug released per unit area.
dh = Change in the thickness of the zone of matrix that has been
depleted of drug.
C0 = Total amount of drug in a unit volume of the matrix.
Cs = Saturated concentration of the drug within the matrix.
From diffusion theory,
dM = (DmCs/h).dt ……………. (2)
Where,
Dm = diffusion coefficient in the matrix.
Equation (1) and (2) integrating and solving for 'h' gives,
M= [CsDm (2Co-Cs) t] 1/2……… (3)
When amount of drug is in excess of the saturation concentration, that is C0>>Cs,
M= [2 Cs Dm C0t] 1/2………… (4)
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Equation (4) indicates that the amount of drug released is a function of the square
root of time.
The drug release from a porous or granular matrix can be described by
M= (Ds.Ca.{P/T}.[2C0-PCa]t)1/2
Where
P = Porosity of the matrix.
T = Tortuosity.
Ca= Solubility of the drug in the release medium.
Ds= Diffusion coefficient in the release medium.
The system is slightly different from the previous matrix system in that the
drug is able to pass out of the matrix through fluid filled channels and does not pass
through the polymer directly. Thus diffusion sustained products are based on two
approaches. The first approach entails placement of the drug in an insoluble matrix
of some sort. The eluting medium penetrates the matrix and drug diffuses out of the
matrix to the surrounding pool for ultimate absorption. The second approach
involves enclosing the drug particle with a polymer coat. In this case the portion of
the drug which has dissolved in the polymer coat diffuses through an unstirred film
of liquid into the surrounding fluid24.
1.9.1 Requirements of matrix materials
The matrix materials must comply with the following conditions,
 They must be completely inert and non-reactive with the drug and
additives in the tablet.
 They must be able to form stable and strong matrices when
compressed either directly or more often as granules prepared by the
addition of a binding agent.
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 They must be non-toxic.
1.9.2 Advantages of Matrix Diffusion System
A hydrophilic matrix system essentially consists of a drug dispersed in water
swelling viscous polymer. These systems offer a number of advantages over other
sustained release technologies namely-
 Unlike reservoir devices, products can be manufactured using conventional
processes and equipments.
 Can deliver high molecular weight compounds.
 Development cost and time associated with matrix system are viewed as
variables, and no additional capital investment is required.
 Simplicity of formulation.
 The system has usually a rate controlling agent GRAS (generally accepted as
safe) food polysaccharides.
 The systems are eroded as they pass the GIT thus there is no accumulation of
“Ghosts” or empty shells.
 As system depends on both diffusion and erosion for drug release, release is
not totally dependent on gastro intestinal motility.
 It is capable of accommodating both low and high drug loading and active
ingredients with a wide range of physical and chemical properties.
 Number of matrix former is available allowing development of formulations
that meet special needs and avoid patient infringement.
 Lastly, it offers easy scalability and process validation due to simple
manufacturing processes.
1.9.3 Disadvantages of Matrix Diffusion System
 Cannot obtain zero order release.
 Removal of remaining matrix is necessary for implanted systems.
1.10 Matrix tablet
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One of the least complicated approaches to the manufacture of sustained
release dosage forms involves the direct compression of blends of drug, retardant
material, and additives to form a tablet in which drug is embedded in a matrix core
of retardant. Sustained-release matrix tablets are formulated so that the active
ingredient is embedded in a matrix of insoluble substance so that the dissolving drug
has to find its way out through the holes in the matrix. In some sustained release
formulations the matrix physically swells up to form a gel, so that the drug first has
to dissolve in the matrix, then exit through the outer surface24. The adjustment of the
polymer concentration, the viscosity grades and addition of different types and
levels of excipients to the polymer matrix can modify the drug release rate23.
1.10.1 Materials used as retardants in matrix tablet formulations.
There must be sufficient polymer content in a matrix system to form a
uniform barrier. The barrier protects the drug from immediately releasing into the
dissolution medium. If the polymer level is too low, a complete gel layer may not
form. In most studies, increased polymer level in the formulation results in
decreased drug-release rates. There are three classes of materials used as retardants
in matrix tablet formulations viz:
1) Insoluble, inert polymers
Tablets prepared from these materials are designed to be egested intact and not
break apart in GI tract. Egested tablets contain unreleased drug in the core.
Examples- Polyethylene
Poly vinyl chloride
Methyl acrylate – methacrylate copolymer
Ethyl cellulose
2) Insoluble, erodible polymers
These form matrices that control release through both pore diffusion and
erosion. Release characteristics are therefore more sensitive to digestive fluid
composition than to the totally insoluble polymer matrix. Total release of drug from
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wax-lipid matrices is not possible, since a certain fraction of the dose is coated with
impermeable wax films.
Examples- Carnauba wax in combination with stearic acid, steryl alcohol
Castor wax
Triglycerides
Poly ethylene glycol
Polyethylene glycol mono stearate
3) Hydrophilic polymers
This group represents non-digestible materials that form gels in situ. Drug
release is controlled by penetration of water through a gel layer produced by
hydration of the polymer and diffusion of drug through the swollen, hydrated matrix,
in addition to erosion of the gelled layer. The extent to which diffusion or erosion
controls release depends on the polymer selected for formulation as well as on drug:
polymer ratio.
Examples- Methyl cellulose
Hydroxy Ethyl cellulose
Hydroxy propyl methyl cellulose
Sodium alginate.
Sodium carboxy methyl cellulose
Poly ethylene oxide
Poly vinyl alcohol
Galacto mannose
Carbopol
Hydroxy propyl cellulose
Guar gum
Alginic acid
Chitosan
Pectin
1.10.2 Types of Matrix Tablets21.
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There are 3 Types of Matrix Tablets
 Hydrophilic matrices
 Fat wax matrices
 Plastic matrices
1) Hydrophilic Matrix Tablet
Hydrophilic matrix is the one where the release-retarding material is water-
swellable or swellable cum erodible hydrocolloid such as high molecular weight.
Hydrophilic matrices containing swellable polymers are referred to as swellable
sustained release systems or hydrophilic matrix tablets. A number of polymers have
been investigated to develop in situ gel-forming systems, due to the ability of these
matrices to release an entrapped drug in aqueous medium and to regulate release of
such drug by control of swelling and cross linking.[rupali kale]  hydroxypropyl
methylcellulose (HPMC), Eudragit, Sodium alginate and Guar gum are the polymers
most widely used as gel-forming agents in the formulation of solid sustained release
dosage forms. Water penetration, polymer swelling, drug dissolution, drug diffusion
and matrix erosion from these dosage forms are controlled by the hydration of
polymer, which forms a gel barrier through which the drug diffuses23.
Examples-
Sodium Carboxy Methylcellulose, Methyl Cellulose, Hydroxy propyl Methyl
Cellulose, Hydroxyl Ethyl cellulose, Polyethylene Oxide, Poly Vinyl Pyrrolidine,
Poly Vinyl Acetate, Gelatin, Natural Gums.
Several commercial patented hydrophilic matrix systems are currently in use,
such as synchron technology and hydrodynamically balanced system.
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Fig.4 Schematic representation of diffusion sustained drug release: matrix
system.
Advantages
 Ease of manufacture.
 Excellent uniformity of matrix tablet.
2) Fat wax matrix tablet
The drug can be incorporated into fat wax granulations by spray congealing
in air, blend congealing in an aqueous media with or without the aid of surfactants
and spray drying techniques.
Examples- Polyethylene, Ethyl cellulose, Glyceryl esters of hydrogenated resins
have been added to modify the drug release pattern.
3) Plastic matrix tablets
With plastic materials, tablets can be easily prepared by direct compression
of drug provided the plastic material can be communited or granulated to desired
particle size to facilitate mixing with drug particles.
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Examples-
Polyvinyl chloride, Polyethylene, Vinyl acetate, Vinyl chloride copolymer,
Vinyllidine chloride, Acrylate (or) Methyl methacrylate copolymer, Ethyl cellulo
se, Cellulose acetate, Polystyrene.
1.11 Dry Granulation 8
When tablet ingredients are sensitive to moisture or are unable to withstand
elevated temperatures during drying, and when the tablet ingredients have sufficient
inherent binding or cohesive properties, slugging may be used to form granules. This
method is referred to as dry granulation, pre-compression, or the double-
compression method. It eliminates a number of steps but still includes weighing,
mixing, slugging, dry screening, lubrication and compression. The active ingredient,
diluents (if one is required), and part of the lubricant are blended. One of the
constituents, either the active ingredient or the diluents, must have cohesive
properties. Powdered material contains a considerable amount of air; under pressure
this air is expelled and a fairly dense piece is formed. The more time allowed for this
air to escape, the better the tablet or slug.
When slugging is used, large tablets are made as slugs because fine powders
flow better into large cavities. The punches should be flat-faced. The compressed
slugs are comminuted through the desirable mesh screen either by hand, or for larger
quantities through the Fitzpatrick or similar comminuting mill. The lubricant
remaining is added to the granulation, blended gently, and the material is
compressed into tablets4. Compression granulation has been used for many years,
and is a valuable technique in situations where the effective dose of drug is too high
for direct compaction, and the drug is sensitive to heat and moisture or both, which
precludes wet granulation. Many drugs such as Aspirin and vitamin formulations are
prepared for tabletting by compression granulation. Other drugs are aspirin
combinations, acetophenetidin, thiamine hydrochloride, ascorbic acid, magnesium
hydroxide, and other antacid compounds.
Compression granulation involves the compaction of components tablet
formulation by means of a tablet press or specially designed machinery, followed by
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milling screening, prior to final compression into tablet. When the initial blend of
powder is forced into the dies of large capacity tablet press and is compacted by
means of flat punches, the compacted masses are called slugs, and process is
referred to as slugging. [Usually, extra large tablet punches are used to form
compressed slugs of the powder material. This procedure is usually slow because the
inherently poor compressibility of the powders requires slower press speeds to
provide the extended compression dwell time under load needed to hold the
compacted material together9. After compression, the slugs are broken down using a
hammer mill or an oscillating granulator to obtain a granulation with a suitable
particle size distribution. It is then screened or milled to produce a granular form of
a tabletting material, which now flows more uniformly than the original powder
mixture. When a single slugging process is insufficient to confer the desired
granular properties to the material, the slugs are sometimes screened, slugged again,
and screened once more.
Slugging is just an elaborate method of subjecting a material to
increased compression time. The act of slugging followed by screening and
subsequent compression of the particles is roughly equivalent to an extended dwell
time during compression in tablet machine. The two or more times that the material
is subjected to compaction pressers causes a strengthening of the bonds that holds
the tablet together. The resultant granules increased the fluidity of the powder
mixtures, which by themselves do not flow well enough to fill the dies satisfactorily.
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Table No 1 Processing steps involved in tablet granulation technique.7
Processing step Wet granulation Dry granulation
Raw material
Weigh
Screen
Mix
Compress(slug)
Wet mass
Mill
Dry
Mill
Mix
Compress
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No
Yes
Yes
Yes
1.11.1 Advantages of Dry Granulation over Wet Granulation8.
 The compression granulation (dry) requires less equipment and steps than
wet granulation.
 Dry granulation technique eliminates the addition of moisture and
application of heat and thus useful for moisture and heat sensitive drugs.
 Dry granulation technique is less time consuming and labour requirement is
less.
 Dry granulation is an economical technique.
 Fewer manufacturing steps.
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1.12 DISEASE PROFILE
Gastro-esophageal reflux disease or (GERD) is defined as a collection of
symptoms that occur when stomach acid and other irritating substances move from
the stomach into the esophagus.
Fig.5 Gastroesophageal reflux
Symptoms of GERD
The symptoms of GERD may include persistent heartburn, acid
regurgitation, and nausea. Some people have GERD without heartburn. Instead they
experience pain in the chest that can be severe enough to mimic the pain of a heart
attack, hoarseness in the morning, or trouble swallowing. Some people also feel like
they have food stuck in their throat or like they are choking. GERD can also cause a
dry cough and a bad breath64. Other common symptoms are belching and hyper-
salivation. Some uncommon symptoms of GERD that would require further
evaluation include cough, asthma, hoarseness and dental erosion. Since the
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symptoms of GERD mimic those of other conditions, it is important to see a
physician for proper diagnosis65.
Causes of GERD
Physical causes of GERD can include a malfunctioning or abnormal lower
esophageal sphincter muscle (LES), hiatal hernia, abnormal esophageal contractions,
and slow emptying of the stomach.  Lifestyle factors that contribute to GERD
include- alcohol use, obesity, pregnancy and smoking. Certain foods can also
contribute to GERD such as citrus fruits, chocolate, caffeinated drinks, fatty and
fried foods, garlic and onions, mint flavorings (especially peppermint), spicy foods,
tomato based foods64.There are few medications that may lower LES pressure which
are: Anticholinergics- amitriptyline, nortriptyline; Barbiturates- Phenobarbital;
Benzodiazepines- diazepam, alprazolam; Estrogen- premarin; NSAID- ibuprofen,
naproxen; Progesterone- medroxyprogesterone, Narcotics- morphine36.
Prevention of GERD
Avoiding alcohol, loss of weight, quit smoking, limited intake of caffeine,
carbonated drink, chocolate, peppermint, tomato and citrus foods, spicy foods, fatty
and fried food, wearing loose clothes around the waist, eating small meals and
slowly, eating last meal of the day three hours before going to bed64.
Diagnosis of GERD
GERD can be diagnosed or evaluated by clinical observation and the
patient’s response to a trial of treatment with medication. In some cases other tests
may be needed including: an endoscopic examination (a long tube with a camera
inserted into the esophagus), biopsy, x-ray, examination of the throat and larynx, 24
hour esophageal acid testing, esophageal motility testing (manometry), emptying
studies of the stomach and esophageal acid perfusion (Bernstein test). Endoscopic
examination, biopsy and assay may be performed as an outpatient in a hospital
setting. Light sedation may be used for endoscopic examination.
Treatment of GERD
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Lifestyle changes are the first-line treatment for patients suffering from mild
GERD. These behavioral changes can be initiated alone or in combination with OTC
medicines (Antacids). If patients do not respond to lifestyle changes or OTC
medicines after two weeks, the next phase of treatment is generally the introduction
of acid-suppressing therapy.
The backbone of acid-suppression therapy centers around the use of H2
receptor antagonists (H2RA’s) and proton pump inhibitors (PPI’s). H2RA’s work by
blocking histamine receptors on gastric parietal cells which helps reduce gastric acid
secretion. 5H2RA’s are generally most effective in mild cases of GERD, but may
lose effectiveness over time since several studies has shown that people may
develop a tolerance to the medication’s side-effects. Members of this medication
class include Axid (nizatidine), Pepcid (famotidine), Tagamet (cimetidine), and
Zantac (ranitidine).
PPI’s show superior effect in the treatment of moderate to severe GERD.
PPI’s work to inhibit acid secretion at the level of acid pump which represents the
final step of acid output in the stomach. It is best to take a PPI thirty minutes to one
hour before first meal so the drug can dissolve and take effect. Members of this
medication class include Aciphex (rebeprazole), Nexium (esomeprazole), Prevacid
(lansoprazole), Prilosec (omeprazole), and Protonix (pantoprazole).
Complications of GERD
GERD is rarely a life-threatening condition, but left untreated it can lead to
some serious consequences. Untreated GERD can b ulcerations, stricture,
hemorrhage, pulmonary aspiration, perforation, and Barrett’s esophagus. Barret’s
esophagus is a pre-malignant change in the lining of the esophagus, which is the
result of long-term contact of stomach acid with the esophagus. Patients who
develop Barret’s esophagus have a 30 to 60 times higher rate of esophageal cancer
compared to the general population.
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FUNCTIONAL DYSPEPSIA67
What is functional dyspepsia?
Dyspepsia refers to group of upper gastrointestinal symptoms that occur
mainly in adults. Dyspepsia is known to result from organic causes, but the majority
of patients suffer from non-ulcer or functional dyspepsia. The generally accepted
definition by most clinicians includes the presence of upper abdominal pain or
discomfort with or without other upper gastrointestinal symptoms, such as nausea,
belching, vomiting, etc. []Functional dyspepsia is sometimes called 'non-ulcer'
dyspepsia. It means that no known cause can be found for the symptoms. That is,
other causes for dyspepsia such as duodenal ulcer, stomach ulcer, acid reflux,
inflamed oesophagus (oesophagitis), gastritis, etc, are not the cause. The inside of
your gut looks normal (if you have an endoscopy - see below). It is the most
common cause of dyspepsia. About 6 in 10 people who have recurring bouts of
dyspepsia have functional dyspepsia.
Causes of functional dyspepsia.
The latest definition of this includes the presence of chronic or recurrent pain
or discomfort centered in the upper abdomen in the absence of any known structural
cause and without any features of irritable bowel syndrome. The precise
pathophysiology of this condition remains unclear, but it is thought to result from a
combination of visceral hypersensitivity, gastric motor dysfunction and
psychological changes. The symptoms seem to come from the upper gut, but the
cause is not known. If you have tests, nothing abnormal is found inside your gut.
The lining inside your gut looks normal and is not inflamed. The amount of acid in
the stomach is normal.
The following are some theories as to possible causes-
 Sensation in the stomach or duodenum may be altered in some way - an
'irritable stomach'. About 1 in 3 people with functional dyspepsia also have
'irritable bowel syndrome' and have additional symptoms of lower abdominal
Chapter-1 Introduction
Department of Pharmaceutics 35 J.K.K. Nattraja College of Pharmacy
pains, erratic bowel movements, etc. The cause of irritable bowel syndrome
is not known.
 A delay in emptying the stomach contents into the duodenum may be a
factor in some cases. The muscles in the stomach wall may not work as well
as they should.
 Infection with a bacterium (germ) called Helicobacter pylori may cause
some cases. This bacterium is found in the stomach in some people with
functional dyspepsia. However, many people are 'carriers' of this bacterium,
and it causes no symptoms in most people. The role of Helicobacter pylori is
controversial in functional dyspepsia (although it is the main cause of
duodenal and stomach ulcers). However, getting rid of Helicobacter pylori
infection helps in some cases.
 Some people feel that certain foods and drinks may cause the symptoms or
make them worse. It is difficult to prove this. Food is not thought to be a
major factor in most cases.
 Anxiety, depression, or stresses are thought to make symptoms worse in
some cases.
 A side-effect of some medicines can cause dyspepsia. The most common
culprits are anti-inflammatory medicines. Various other medicines which
sometimes cause dyspepsia, or make dyspepsia worse, include: digoxin,
some antibiotics, steroids, iron, calcium antagonists, nitrates, theophyllines,
and bisphosphonates.
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2. LITERATURE REVIEW
M Sakashita* et.al., (1993): studied the effect of pharmacokinetics of the
gastrokinetic agent mosapride citrate after single and multiple oral administrations in
healthy subjects. The pharmacokinetics and dose proportionality of mosapride
citrate (±) 4-amino-5-chloro-2-ethoxy-N-[[4- (4-fluorobenzyl)-2-morpholinyl]
methyl] benzamide citrate dihydrate, were investigated in healthy male volunteers.
The subjects were given a single oral dose (5, 10, 20 and 40 mg, each of 5 subjects)
and a multiple oral dose (20 mg t.i.d. for one day, and 10 and 20 mg t.i.d. for 8 days,
each of 5 subjects). Food effect on the pharmacokinetics of mosapride was also
evaluated after a single oral 10 mg dose by an open, two-way crossover method.
Mean plasma levels of mosapride reached a peak 0.5-1 h after single dosing of 5, 10,
20 and 40 mg. The peaks were dose-related with values of 25.1, 51.2, 157.8 and
280.6 mg/ml, respectively, and were followed by a first-order decrease with
apparent half-lives of 1.4-2.0 hours. The Cmax and AUC increased in proportion to
the dose, indicating linear pharmacokinetics of mosapride up to 40 mg. The Cmax of
M-1, a des-4-fluorobenzyl metabolite, was 1/6 of that of the unchanged drug.
Urinary excretion of the unchanged mosapride and M-1 during 48 h after single
dosing accounted for 0.1-0.4% and 7.0-11.0% of the dose, respectively. There were
no significant changes in the plasma concentration-time profiles and urinary
excretions between single and multiple doses, indicating that the pharmacokinetics
of mosapride in man was not altered by its multiple administrations. Plasma levels
of Mosapride reached steady state on day 2 of multiple administrations.16
Anroop B. Nair * et.al., (2010): formulated controlled release matrix uncoated
tablets of Enalapril Maleate using HPMC alone. Direct compression technique was
used to prepare the tablets, and these tablets were evaluated for physical properties,
drug content, in vitro release and drug release kinetics as well. All the formulations
demonstrated good physical integrity and the drug content were in the official limits.
The formulations with HPMC K 100 (25mg/tablet) and K4M (15mg/tablet) have
been found to release the required amount of drug (2.97mg/h) throughout the study
period (14h). The calculated regression coefficients showed higher r2 value with
Higuchi model and zero order kinetics. Given the excellent release profile, the study
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concluded that HPMC in different grades with low concentration alone can control
the enalapril maleate release over a period of 14hours.
Bhupendra G. Prajapati* et.al., (2010): developed matrix sustained release tablets
of water soluble prokinetic agent which is itoporide Hydrochloride. Two polymer
grades of HPMC-K4M and K100M along with ethyl cellulose and pregelatinised
starch were used in different batches of formulations. The release rates of drug from
individual as well as combined polymers were studied. The optimized formulation
was found to be the one in which a combination of polymers of HPMC K4M and
HPMC K100M were used i.e F11. It was found that the drug was completely
released from the optimum formulation and the drug release was also extended to 12
hours. This study indicates that by using the combination of these polymers we can
obtain good control on the release profile of water soluble drug and sustained release
can be obtained.
Deepak Kumar Mourya* et.al., (2010): studied the formulation and release
characteristics of novel monolithic HPMC matrix tablets containing metronidazole.
The excipients used were HPMC, Starch 1500, sodium lauryl sulphate,
microcrystalline cellulose, and sodium dihydrogen phosphate. The tablets contained
500mg metronidazole and different drug polymer ratios of HPMC. The m- HPMC
tablets were prepared using a wet granulation method followed by direct
compression. Sustained released matrix tablets were found to be highly influenced
by amounts of m-HPMC polymer polymer incorporated. Results showed that
granules can be used to prepare in terms of micromeritic properties and flow
behaviour. Findings of the results showed that batchF1 have maximum drug release
while F6 have minimum drug release. It can be concluded from the obtained results
that as the concentration of HPMC increases, % drug release decreases.
Syed Namath Ulla* et.al., (2011): formulated matrix sustained release tablets of
lornoxicam by using different viscosity grades of HPMC polymers namely HPMC
K4M, HPMC K15M, HPMC K100M. A total number of nine formulations were
prepared by direct compression technique using 6mm flat punches to an average
weight of 120 mg. The optimum formulation was found to be F1 which comprises of
HPMC K4M alone. A sustained release pattern was obtained for 12 hours from the
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optimum formulation F1. The hydrophilic matrix of HPMC controlled the
Lornoxicam release effectively. The order of drug release from the selected
polymers were found to decrease in the following order HPMC K4M> HPMC
K15M> HPMCK100M.
Dr. Ritesh Patel* et.al., (2009): studied the optimization of propranolol
hydrochloride controlled release matrix tablet using factorial design. Direct
compression technique was involved. HPMC K15M and Carbopol 934P were used
in formulating the matrix tablets. A 32 full factorial design were applied for
systemic studies. The blending ratio of HPMC K15M and Carbopol 934P (X1) and
polymer concentrations (X2) were the independent variables. The times required for
50% (t50) and 80% (t80) drug release were selected as dependent variables. The
results indicated that the values of t50, t80, f2 and MDT are strongly dependent on
the independent variables. in vitro drug release profile of all batches of factorial
design was compared with theoretical drug release profile. The results indicated that
batch F7 showed the highest value among all the batches, and it also shows
similarity in t50 and t80 values. The f2 value (74) of batch F7 indicates less than 5%
difference in in vitro drug release profile with theoretical release profile.
Margret Chandira* et.al., (2009): formulated sustained release matrix tablets of
Zidovudine by using two different grades of HPMC polymers- HPMC K15M and
HPMC K100M. A total of eight formulations were prepared. The first 3
formulations were made by direct compression technique and the rest of the
formulations were prepared by wet granulation technique. The formulation B8 had
given the optimum release till 12 hours which includes HPMCK100 alone as
polymer and so this was taken as the optimized formulation and coating was done.
N. N. Rajendran* et.al., (2010): formulated and evaluated sustained release bilayer
tablets of metformin hydrochloride and pioglitazone hydrochloride. Sustained layer
were prepared by wet granulation method using different viscosity grade of
hydroxypropyl methyl cellulose (HPMC K4M and HPMC K100M) as polymers and
immediate release layer were prepared by direct compression method using
superdisintegrants such as sodium starch glycolate and crosscarmellose sodium. The
tablets were evaluated for physicochemical properties. The values were found within
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the limits. In vitro release studies were carried out by USP type-2 paddle apparatus.
The result showed that combinations of polymers namely HPMC K4M and HPMC
K100M in sustained layer can control the release of drug. The in vitro release
profiles of drug from sustained release layer could be best expressed by Higuchi’s
equation as the plots showed high linearity (R2>0.988) and diffusion was the
dominant mechanism of drug release. The formulations (P6M7) having immediate
release layer produces immediate effect within 54 seconds followed by sustained
release (97.35%) at 8 hours and it is comparable with the innovator’s brand. The
present study concluded that bilayer tablets of these drugs can serve as an alternative
to the conventional dosage form.
Anna Korner* et.al., (2009): studied the effect of three different types of polymer
chain structures on the polymer release from hydrophilic matrix tablets by
comparing a synthetic semi-crystalline linear polymer (PEO), a branched amorphous
polysaccharide (dextran) and an amorphous substituted cellulose derivative
(HPMC). The results showed that independent of polymer type plots of the release
versus time had similar shapes, the release of long and short polymer chains was
equal and no fractionation occurred during the release and the release rate could be
related to the average intrinsic viscosity of the polymer mixtures. This confirms the
hypothesis that the release rate can be related to a constant viscosity on the surface
of the hydrophilic matrix tablet and that it is valid for all the investigated polymers.
Subramaniam Kannan* et.al., (2010): formulated and evaluated sustained release
tablets of aceclofenac using hydrophilic matrix system. A once daily sustained
release tablets of aceclofenac (200mg) were prepared by wet granulation technique
and using hydrophilic polymer like hydroxypropyl methyl cellulose k-100. The
tablets were subjected to physicochemical studies, in-vitro drug release, kinetic
studies and stability studies. The drug release from optimized formulations was
extended for a period of 24 hours. The kinetic treatment of selected formulation (F8)
showed that the release of drug follows zero order models. Stability studies were
also carried out. Results of the present study indicated the suitability of hydrophilic
polymers in the preparation of matrix based sustained release formulation of
aceclofenac.
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Dinanath Gaikwad* et.al; (2011): formulated and evaluated sustained release
tablet of aceclofenac by film coating. The drug has a short half life so it was film
coated with HPMC (E5 LV). The incorporation of aceclofenac was performed in
inert HPMC. This polymer was used in different concentrations to achieve sustained
release kinetics for the drug. From the dissolution studies, it was observed that all
batches gave the release by diffusion-dissolution controlled mechanism. The
dispersion of the drug in the polymer network altered its dissolution profile at pH
6.8, thus making it possible to obtain a gradual and prolonged release, and to
modulate the release pattern. Optimized batches show similarity with market
product and give sustained release till 12 hours.
Rupali Kale* et.al., (2010): developed matrix diffusion controlled drug delivery
system of pentoxifylline. HPMC formulations showed very high dissolution rate
releasing 70% of drug within two hours but its combination formulation with
eudragit showed low dissolution rate of 0.14 hour-1. Sodium alginate used did not
show controlled drug release pattern. Eudragit and Guar gum formulations showed
low dissolution rates indicating controlled release pattern of drug but their
combination formulation showed high dissolution rate of 0.73 hour-1.
Tapan Kumar pal* et. al., (2007): formulated and optimized sustained release
matrix tablets of metformin hydrochloride 500mg using response surface
methodology. Tablets were prepared by non-aqueous wet granulation method using
HPMC K 15M as matrix forming polymer. A central composite design for 2 factors
at 3 levels each was employed to systematically optimize drug release profile.
HPMC K 15M (X1) and PVP K 30 (X2) were taken as the independent variables.
The dependent variables were percentage of drug released in one hour (rel1 hour),
percentage of drug released in 8 hours (rel8 hours) and time to 50% drug release (t50%).
Contour plots were drawn, and optimum formulations were selected by feasibility
and grid searches. The formulated tablets followed Higuchi drug release kinetics and
diffusion was the dominant mechanism of drug release, resulting in regulated and
complete release within 8 hours. The polymer (HPMC K 15M) and binder (PVP K
30) had significant effect on the drug release from the tablets (p<0.05). Validation of
optimization studies were performed using 8 confirmatory runs, indicated very high
degree of prognostic ability of response surface methodology, with mean percentage
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error (±S.D) 0.0437±0.3285. Besides unravelling the effect of the 2 factors on the in
vivo drug release, the study helped in finding the optimum formulation with
sustained drug release.
Saravanan M*, Nataraj K S, Ganesh K S et.al., (2003): studied hydroxypropyl
methylcellulose based cephalexin extended release tablets: Influence of tablet
formulation, hardness and storage on in vitro release kinetics. The object of this
study was to develop hydroxypropyl methylcellulose (HPMC) based cephalexin
extended release tablet, which can release the drug for six hours in predetermined
rate. The influences of HPMC, microcrystalline cellulose powder (MCCP),
granulation technique, wetting agent and tablet hardness on cephalexin release from
HPMC based extended release tablets were studied. The dissolution results showed
that a higher amount of HPMC in tablet composition resulted in reduced drug
release Tablets prepared by dry granulation was released the drug slowly than the
same prepared with a wet granulation technique. Addition of wetting agent in the
tablets prepared with dry granulation technique showed slower release. An increase
in tablet hardness resulted in faster drug release. The in vitro release data was well
fit in to Higuchi and Korsmeyer-Peppas model. Physical and chemical parameters of
all formulated tablets were within acceptable limits22
Anthon smith* et.al., (2009): developed sustained release matrix tablets of
ondasetron hydrochloride by employing HPMC K4M, HPMC K15M and HPMC
K100M polymers and sustained release behaviour of the tablet was investigated.
Tablets were prepared by wet granulation technique.
Marina Levina, et al., (2004): Studied influence on drug release from HPMC
matrix system. The influence of commonly used excipients such as spray dried
lactose, microcrystalline cellulose and partially pregelatinized maize starch on drug
release from HPMC matrix system has been investigated, model formulation
contained 30% w/w drug, 20%w/w HPMC ,0.5%w/w fumed silica, 0.25%w/w
magnesium stearate and 49.25%w/w filler. Chlorphenaramine maleate and
theophyline were used freely (1in 4) and slightly (1in 120) water soluble drugs,
respectively. It was found that for both the drug addition of 20-49.2%w/w starch
1500 resulted in significant reduction in drug release rate compared to when MCC
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and lactose was used. The studies showed that using lactose or MCC in the
formulation resulted in faster drug release profiles.23
European Patent EP0895780  (2002): this invention relates to pseudo ephedrine
hydrochloride extended-release tablets which comprise a sustained release
hydroxypropyl methylcellulose matrix, a microcrystalline cellulose disintegrant, and
a filler and which are formed by a dry granulation, direct compression method. A
method for forming these caplets is al so disclosed.50
Md. Selim Reza, et al., (2002): developed sustained release theophyllin matrix
tablets kollidon SR. Four matrix formulations were prepared by dry blending and
direct compression method by varying proportion of HPMC, with fixed percentage
of theophyline. Tablets containing ingredient demonstrated a rapid rate of drug
release with an initial burst effect. Incorporation of HPMC-15cps, in the drug with
subsequent minimization of burst effect as confirmed by mean dissolution time, a
direct relationship was obtained between release rate and percentage of HPMC-
15cps profile was obtained with the matrix tablets containing 30% HPMC-15cps,
and 20% kollidon SR. It was found that, fickian release is predominant in tablets.29
Outi Honkanen. et. al., (2002): studied the Bioavailability and in vitro esophageal
sticking tendency of hydroxypropyl methylcellulose capsule formulations and
corresponding gelatin capsule formulations in the present study was to widen our
knowledge about the biopharmaceutical behavior of novel hydroxypropyl
methylcellulose (HPMC)-based two-piece capsules by comparing them with the
classic hard gelatin capsules. Firstly, the tendency of the HPMC capsules to stick to
isolated porcine esophageal preparation was evaluated. The force needed to detach
the HPMC capsules from the esophagus was significantly lower than that for the
gelatin capsules (P<0.001), which is evidently an advantage of this new dosage
form. The second aim was to investigate the possibility of preparing sustained-
release capsules using different powdered HPMC as diluents (K100, K4M and
K15M) and the effect of the molecular weight of HPMC powder on the in vitro and
in vivo behavior of the capsules. Using different viscosity grades of HPMC powders
as diluents it was possible to control the absorption rate of the model drug both from
gelatin and HPMC capsules as far as the oral route was concerned.13
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Yan G. et al., (2000): Prepared and evaluated sustained release tablets of nifedipine
by using HPMC as polymer. A nifedipine, polyethylene glycol solid dispersion was
prepared; using solid dispersion method. Both the high viscosity grade HPMC K-
15M and low viscosity grade viscosity were applied in the tablet to form the matrix.
The dissolution stand the absorption of nifedipine from the tablet was evaluated as
the formulation that has sustained release over 24 hours. Hixon-Crowell equation
and Higuchi equation were used to investigate the dissolution and the erosion and
diffusion co dependent mechanism was established.45
M. Victoria Velasco*, et. al., (1999): studied the influence of drug: hydroxypropyl
methyl cellulose ratio, drug and polymer particle size and compression force on the
release of diclofenac sodium from HPMC tablets. This study evaluates the
relationship and influence of formulation and technological factors such as drug:
hydroxypropyl methyl cellulose (HPMC) ratio, particle size of the drug, particle size
of HPMC and compression force, on drug release from matrices containing HPMC
and diclofenac sodium as a model drug. The influence of these variables was
assessed by multi-way analysis of variance. The results of the present study point
out that the rate and mechanism of diclofenac sodium release from HPMC K15M
matrices are mainly controlled by the drug: HPMC ratio. The drug and HPMC
particle size also influence the drug release parameters, although to a lesser extent.
Finally, the independence of the drug release from matrix tablets with respect to the
compression force is reported.11
Naoyuki Yoshida* et.al., (1999): studied the pharmacological effects of mosapride
Citrate, and reported that mosapride dose- dependently enhanced gastric emptying
of a liquid or solid meal in rats with potency equal to that of cisapride and more
potent than that of metaclopramide. In rats mosapride improved the gastric emptying
delayed by gastro duodenal surgical invention, mosapride had no affinity for
dopamine D2 receptors, where as metaclopramide and cisapride had high affinity for
dopamine D2 receptor. In conclusion, mosapride is a selective and potent 5HT4
receptor agonist and improves gastrointestinal symptoms in a patients with non-ulcer
dyspepsia without causing extra pyramidal syndrome associated with dopamine D2-
receptor blockage and adverse cardiovascular effects such as torsadose de points.17
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3. AIM AND OBJECTIVE
Oral ingestion has long been the most convenient and commonly employed
route of drug delivery. Indeed, for sustained-release systems, the oral route of
administration has by far received the most attention with respect to research on
physiological and drug constraints as well as design and testing of products.
The aim of the present study was to formulate and evaluate sustained release
matrix tablets of mosapride citrate using hydrophilic polymer hydroxypropyl
methylcellulose (HPMC) alone, of two different viscosity grades of hydroxypropyl
methylcellulose (HPMC K4M & HPMC K15M.).
Mosapride citrate has a short half life 1.4 -2.0 hours and usual oral dosage
regimen of 5 mg 3-4 times daily. And thus the objective was to reduce the frequency
of administration and to improve patient compliance; a once-daily sustained release
formulation of mosapride citrate was formulated.
The most commonly used method of modulating the drug release is to
include it in a matrix system. Hydrophilic polymer matrix systems were widely used
in oral controlled drug delivery because they make it easier to achieve a desirable
drug-release profile, they are cost effective and they have US Food and Drug
Administration acceptance.
The viscosity of hydroxypropyl methylcellulose polymer influences the
erosion rate of matrix tablet. In other words, the rate of tablet erosion can be
adjusted by the choice of hydroxypropyl methylcellulose polymer viscosity or by
mixing hydroxypropyl methylcellulose polymer of varying viscosities. So, in order
to study the effect of viscosity of polymer on erosion of matrix tablet, two different
viscosity grades of hydroxypropyl methylcellulose were used.
Hence, in present work, an attempt has been made to develop once-daily
sustained release matrix tablets of mosapride citrate using hydrophilic matrix
materials such as hydroxypropyl methylcellulose with two different viscosity grades
( HPMC K4M & HPMC K15M).The lower viscosity grade of hydroxypropyl
methylcellulose (HPMC K4M) sustain the drug release up to 12 hrs, for further
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sustaining the release of drug up to 24 hours from matrix of the tablet, the higher
viscosity grade of hydroxypropyl methylcellulose (HPMCK15M) is useful. So in
present study the combination of two different viscosity grades of hydroxypropyl
methylcellulose were used.
In present study sustained release matrix tablets of mosapride citrate was
compressed by using dry granulation/slugging technique. The dry granulation /
roller compaction technique is especially useful for the drugs that are sensitive for
heat, moisture. Mosapride citrate is moisture, heat sensitive drug hence the dry
granulation / roller compaction technique is useful.
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4. PLAN OF WORK
The present work was carried out to formulate and evaluate the sustained
release matrix tablets of mosapride citrate using polymers like HPMC (K4M &
K15M). This work was carried out as outlined below.
Stage1 : Procurement of drug and raw materials.
Stage2 : Preformulation studies by using Fourier
Transform Infra red spectrometer (FTIR)
Stage3 : Preparation of Mosapride citrate matrix tablets
by dry granulation method.
Stage4 : Standard Graph of Mosapride citrate in Acetate
Buffer pH 4.0
Stage5 : Characterization of physical mixture / granules
 Bulk density
 Tapped density
 Angle of repose
 Carr’s index
 Hausner’s ratio
Stage6 : Characterization of granules prepared matrix
tablets.
 Uniformity of weight.
 Thickness variation test
 Hardness test.
 Friability test.
 In vitro dissolution study.
Stage7 : Kinetics studies.
Stage 8 : Stability studies.
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5. THEORETICAL BACKGROUND17,29, 39, 51,68,69,70
5.1 Drug Profile
Mosapride citrate
Structure:
C
Cl
O
H
N
H2
C
N
O
NH2
OC2H5
H2C F
CH2COOH
C(OH)COOH
CH2COOH
.
Chemical name: (±)-4-Amino-5chloro-2-ethoxy-N-[[4-(4-flurobenzyl)-2-
2morpholinyl] methyl] benzamide citrate.
Description: an off white crystalline powder.
Physical properties-
Solubility: soluble in DMF.
Residue on ignition: not more than 0.1w/w.
Molecular formula: C21H25ClFN3O3.C6H8O7.2H2O.
Molecular weight: 650.50
Melting point: 110-113°C
Pharmacokinetics-
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Absorption: Mosapride is quickly absorbed after oral ingestion. Absorption
is unaffected by the presence of food.
Distribution: Mosapride is 93-99% bound to plasma protein, including
albumin and alpha-1- acid glycoprotein. The drug is distributed to most body tissues,
more to the gastrointestinal tract than to the brain. Mosapride achieves high levels in
milk and crosses the placenta.
Half life: 1.4-2.0 hours.
Metabolism: Most drugs are metabolized and negligible amount of
unchanged drug is appeared in urine. The drug is degraded in the liver by cytocrome
P-450(3A4) pathway. Only 0.1 to 4% is excreted in the urine. M-1 is a des-4-
flurobezyl metabolite and is the cheep degradation product of mosapride. M-2 is
another metabolite, and is very little activity. The metabolites thus contribute very
little to the gastro-prokinetic activity of Mosapride. However M-1 is a 5HT-3
antagonist with significant potency.
Mechanism of action: Mosapride is an agonist of 5HT-4 receptor. 5HT-4 receptors
are present in the gut in the myenteric plexus, in the neurons of the longitudinal and
circular muscles, and in the gut interneuron’s. On stimulation the receptors result in
neuronal release acetylcholine, which causes increased motility and hyper secretion.
Mosapride increases gastric emptying. Mosapride has affinity only for receptors
located in the foregut, and does not stimulate colonic receptors, and therefore rarely
causes diarrhoea. In contrast, Cisapride and tegaserod increases colonic motility and
result in diarrhoea.
The specificity extends to a lack of affinity to D2 receptors in the brain, in
comparison to other prokinetic agents. Mosapride does not influence the QT interval
even at higher doses.
Adverse effects: Abdominal cramps, headache, dry mouth, nausea.
Interactions: Mosapride’s major degradation is the cytocrome P-450 (3A4) system.
However, electrophysiological study show that the co administration of drugs that
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inhibits the CYP3A4 enzymes, (Erythromycin, ketoconazole, flucanazole, etc.)
Have no effect on mosapride indicating that the satisfactory safety margin exists in
relation to rhythm abnormalities, unlike that which occurs with Cisapride.
Indications: Gastro-esophageal reflux diseases (GERD).
Functional dyspepsia.
Diabetic gastropathy.
Disorders associated with decreased gastric motility.
Dosage: Oral 5 mg three times a day.
Storage: Store at 15-30°C in tightly closed container, protect from heat and light.
Keep out of reach of children.
5.2 EXCIPIENTS PROFILE10
HYDROXY PROPYL METHYL CELLULOSE (HPMC)
OO O
CH2OR
O
RO OR
RO OR
CH3CH2OR
CH3
R=H, CH3 or CH3CH (OH)
Chemical Name: Cellulose 2-hydroxyl Propyl methyl ether
Nonproprietary names: Cellulose, Hypromellose, 2-Hydroxypropyl methyl ether,
Methyl Hydroxy Propyl cellulose, Hypromellosum (ph Eur), Methocel, Pharmacoat,
Metolose.
Chapter-5                                                                          Drug and Excipient Profile
Department of Pharmaceutics 47 J.K.K. Nattraja College of Pharmacy
Synonym: Benecel MHPC, e464, Methylcellulose propylene glycol ether,
Pharmacoat, Tylopur, Tylose MO.
Molecular Weight: 10000-1500000
Description: Hypromellose is an odorless and tasteless white or creamy white
fibrous or granular free flowing powder.
Physical properties-
Solubility: Soluble in cold water, forming a colloidal solution; practically
insoluble in hot water, dehydrated alcohol, chloroform and ether. It undergoes
reversible transformation from solution to gel on heating and cooling respectively.
pH: A 1%w/w solution has a pH of 5.5-8.0.
Melting Point: Browns at 190-2000C; chars at 225-2300C; Tg is at 170-
1800C.
Auto ignition Temperature: 3600C
Bulk Density: 0.341 gm/cm3
Tapped Density: 0.557 gm/cm3
Gel Formation: Undergoes a reversible transformation from solution to gel
upon heating and cooling respectively.
Gel point: 50-9000C
Storage: Stored in well closed containers.
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Table No 2: Various grades of Hypromellose varying in viscosity and extent of
substitution.
Methocel Grade Nominal Viscosity (mPas)
K100LVP 100 80-120
K4M 4000 3000-5600
K15M 15000 12000-21000
K100MP 100000 80000-120000
E4MP 4000 3500-5600
E10MP CR 10000 8000-13000
E3 PREM. LV - 2.4-3.6
E5PREM. LV - 4-6
E6PREM.LV - 5-7
E15PREM.LV - 12-18
E50PREM.LV - 40-60
K3PRem.LV - 2.4-3.6
Note: HPMC is prepared by reacting alkali-treated cellulose first with methyl
chloride to introduce methoxy groups and then with propylene oxide to introduce
propylene glycol ether groups.4
Applications in pharmaceutical formulation and Technology:
Widely used in oral and topical pharmaceutical formulations.
Concentrations between 2% and 5% w/w may be used as a binder in either
wet or dry granulation processes.
High viscosity grades may be used to retard the release of drugs from the
matrix at levels of 10-80% w/w in tablets and capsules.
Low viscosity grades are used in aqueous film coating.
Useful as a dispersing and thickening agent.
In ophthalmic solutions to provide demulcent action4.
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MAGNESIUM STEARATE
Nonproprietary Names: Magnesium stearate (BP), Magnesium stearate (JP),
Magnesium stearas (PhEur), Magnesium stearate (USPNF)
Synonyms: Magnesium octadecanoate, octadecanoic acid, magnesium salt, stearic
acid, magnesium salt.
Description: Magnesium stearate is a very fine, light white, precipitated or milled,
impalpable powder of low bulk density, having a faint odor of stearic acid and a
characteristic taste. The powder is greasy to the touch and readily adheres to the
skin.
Chemical Name and CAS Registry Number: Octadecanoic acid magnesium salt
[557-04-0]
Empirical Formula and Molecular Weight: C36H70MgO4 591.34
The USPNF 23 describes magnesium stearate as a compound of magnesium
with a mixture of solid organic acids that consists chiefly of variable proportions of
magnesium stearate and magnesium palmitate (C32H62MgO4). The PhEur 2005
describes magnesium stearate as a mixture of magnesium salts of different fatty
acids consisting mainly of stearic acid and palmitic acid and in minor proportions
other fatty acids.
Structural Formula: [CH3 (CH2)16COO] 2Mg
Functional Category: Tablet and capsule lubricant.
Applications in Pharmaceutical Formulation or Technology: Magnesium
stearate is widely used in cosmetics, foods, and pharmaceutical formulations. It is
primarily used as a lubricant in capsule and tablet manufacture at concentrations
between 0.25% and 5.0% w/w. It is also used in barrier creams.
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TALC
Synonyms: Altalc; E553b; hydrous magnesium calcium silicate; hydrous
magnesium silicate; powdered talc.
Chemical Name: Talc
Nonproprietary Names: Purified talc (BP), Talc (JP), Talcum (PhEur), Talc (USP).
Functional Category: Anticaking agent, glidant, tablet and capsule diluent, tablet
and capsule lubricant.
Description: Talc is a very fine, white to grayish- white.
Properties:
Density (bulk): 0.159 g/cm3
Density (tapped):0. 286 g/cm3
Density (true): 1.092 g/cm3
Melting range: 117-1500C (commercial samples)
126-1300C (highly pure)
LACTOSE, ANHYDROUS
Nonproprietary Names: Anhydrous lactose (BP), Anhydrous lactose (JP),
Lactosum anhydricum (PhEur), Anhydrous lactose (USPNF)
Synonyms: Anhydrous Lactose NF 60M; Anhydrous Lactose NF Direct Tabletting;
Lactopress Anhydrous; lactosum; lattioso; milk sugar; Pharmatose DCL 21;
Pharmatose DCL 22; saccharum lactis; Super-Tab Anhydrous.
Chemical Name and CAS Registry Number: O-β-d-galactopyranosyl-(1→4)-β-d-
glucopyranose [63-42-3]
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Empirical Formula and Molecular Weight: C12H22O11 342.30
Description: white or creamy white, hard, crystalline masses or powder;odourless,
and has a faintly sweet taste; stable in air, but readily absorbs odors.
Structural Formula:
Melting point: 223.0°C for anhydrous α-lactose;
252.2°C for anhydrous β-lactose;
232.0°C (typical) for commercial anhydrous lactose.
Solubility: 1g in 5ml water and 2.6 ml boiling water. Sparingly soluble in ethanol
(95%) and insoluble in chloroform and ether.
Functional Category: Binding agent, directly compressible tabletting excipients,
lyophilization aid, tablet and capsule filler.
Applications in Pharmaceutical Formulation or Technology:
Anhydrous lactose is widely used in direct compression tabletting
applications and as a tablet and capsule filler and binder. Anhydrous lactose can be
used with moisture-sensitive drugs due to its low moisture content. Lactose occurs
as white to off-white crystalline particles or powder. Several different brands of
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anhydrous lactose are commercially available which contain anhydrous β-lactose
and anhydrous α-lactose. Anhydrous lactose typically contains 70–80% anhydrous
β-lactose and 20–30% anhydrous α-lactose.used as a diluent in medicine and
pharmacy. It is generally an ingredient of the medium used in penicillin production.
It is extensively used as an addition to milk for infant feeding.remington-1262
Incompatibilities: Lactose anhydrous is incompatible with strong oxidizers. When
mixtures containing a hydrophobic Leukotriene antagonist and anhydrous lactose or
lactose monohydrate were stored for six weeks at 40°C and 75% RH, the mixture
containing anhydrous lactose showed greater moisture uptake and drug degradation.
Note: It is prepared from skim milk, to which is added dilute hydrochloric acid to
precipitate the casein. After removal of the casein by filtration, the reaction of the
whey is adjusted to ph 6.2 by adding lime and remaining albuminous matter is
coagulated by heating. This is filtered and liquid set aside to crystallize. Animal
charcoal is used to decolorize the solution.
COLLOIDAL SILICON DIOXIDE
Nonproprietary Names: Colloidal anhydrous silica (BP), Silica colloidalis
anhydrica (PhEur), Colloidal silicon dioxide (USPNF).
Synonyms: Aerosil; Cab-O-Sil; Cab-O-Sil M-5P; colloidal silica; fumed silica;
light anhydrous silicic acid; silicic anhydride; silicon dioxide fumed; Wacker HDK.
Description: Colloidal silicon dioxide is submicroscopic fumed silica with a
particle size of about 15 nm. It is a light, loose, bluish-white-colored, odorless,
tasteless, non-gritty amorphous powder.
Chemical Name and CAS Registry Number: Silica [7631-86-9]
Empirical Formula and Molecular Weight: SiO2 60.08
Structural Formula: SiO2
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Functional Category: Adsorbent, anticaking agent, emulsion stabilizer, glidant,
suspending agent, tablet disintegrant, thermal stabilizer and viscosity-increasing
agent.
Applications in Pharmaceutical Formulation or Technology:
Colloidal silicon dioxide is widely used in pharmaceuticals, cosmetics, and food
products; its small particle size and large specific surface area give it desirable flow
characteristics that are exploited to improve the flow properties of dry powders in a
number of processes such as tabletting. Colloidal silicon dioxide is also used to
stabilize emulsions and as a thixotropic thickening and suspending agent in gels and
semisolid preparations. With other ingredients of similar refractive index,
transparent gels may be formed. The degree of viscosity increase depends on the
polarity of the liquid (polar liquids generally require a greater concentration of
colloidal silicon dioxide than non-polar liquids). Viscosity is largely independent of
temperature. However, changes to the pH of a system may affect the viscosity.
Solubility: Practically insoluble in organic solvents, water, and acids, except
hydrofluoric acid; soluble in hot solutions of alkali hydroxide forms a colloidal
dispersion with water.
Stability and Storage Conditions: Colloidal silicon dioxide is hygroscopic but
adsorbs large quantities of water without liquefying. When used in aqueous systems
at a pH 0–7.5, colloidal silicon dioxide is effective in increasing the viscosity of a
system. However, at a pH greater than 7.5 the viscosity-increasing properties of
colloidal silicon dioxide are reduced; and at a pH greater than 10.7 this ability is lost
entirely since the silicon dioxide dissolves to form silicates. Colloidal silicon dioxide
powder should be stored in a well-closed container.
Some grades of colloidal silicon dioxide have hydrophobic surface treatments that
greatly minimize their hygroscopicity.
Incompatibilities: Incompatible with diethylstilbestrol preparations.
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6. MATERIALS AND EQUIPMENTS
Material Company Name
1. Mosapride Citrate DR. Reddy’s Holdings limited,
Hyderabad.
2. HPMC K15M Colourcon Asia Pvt. limited, Mumbai
3. HPMC K4M Colourcon Asia Pvt. limited, Mumbai
4. Lactose Concept pharmaceuticals limited,
Aurangabad.
5. Magnesium stearate Concept pharmaceuticals limited,
Aurangabad
6. Aerosil 200 Concept pharmaceuticals limited,
Aurangabad
7. Talcum Concept pharmaceuticals limited,
Aurangabad
EQUIPMENTS
11. Single punch tablet rotary machine Cadmach
12. Dissolution apparatus Electro lab (Model: TDT-06P,
Aurangabad).
13. UV Visible spectrophotometer Shimadzu (UV 1700)
14. Hardness tester Monsanto
15. Friabilator Electro lab
16. Vernier caliper Baker
17. pH meter Control Dynamic
18.  FTIR Shimadzu
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METHODOLOGY
PREFORMULATION STUDIES
Prior to development of any dosage form, it is essential that certain
fundamental physical and chemical properties of the drug molecule and other
derived properties of the drug powder are determined. This information will dictate
many of subsequent events and possible approaches in formulation development.
This first learning phase is called as preformulation.71
Bulk Density12
It is the ratio of a given mass of a powder and its bulk volume.
Procedure:
Bulk density (gm/ml) is determined by pouring presieved (40-mesh) bulk
drug into a graduated cylinder via a large funnel and measuring the volume and
weight9.
Mass of powder
Bulk Density =
Bulk Volume of the powder
Tapped Density12
Tapped density is the ratio of mass of powder to that of tapped volume of the
powder.
Procedure:
Tapped density is determined by placing a graduated cylinder containing a
known mass of the drug or formulation on a mechanical tapper apparatus, which is
operated for a fixed number of taps (~1000) until the powder bed volume has
reached a minimum. Using the weight of drug in the cylinder and this minimum
volume, the tapped density may be computed.
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Weight of powder
Tapped density =
Tapped volume of the powder9
Carr’s Index8
A simple indication of the ease with which a material can be induced to flow
is given by application of a compressibility index (I), given by the equation
I= [1- Tapped density / Bulk density] x 100.
Values of I below 15% usually give rise to good flow characteristics, but readings
above 25% indicate poor flow ability9.
Table No.3 Standard range of Carr’s Index.
Carr’s Index Type of flow
5-15 Excellent
12-18 Good
18-23 Fair to passable
23-35 Poor
35-38 Very poor
Above 40 Extremely poor
Hausner’s Ratio71
Hausner’s ratio is defined as the ratio of tapped density to poured density.
Tapped density
Hausner’s ratio =
Poured Density
Values less than 1.25 (= 25% Carr’s index) indicates good flow, while
greater than 1.25 indicates poor flow (= 33% Carr’s index). Between 1.25 and 1.5
added glidants normally improves flow.
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Table No.4 Standard range of Hausner’s Ratio.
Hausner’s Ratio Type of flow
1.00 - 1.11 Excellent
1.12 - 1.18 Good
1.19 - 1.25 Fair
1.26 - 1.34 Passable
1.35 – 1.45 Poor
1.46 – 1.59 Very poor
Above 1.60 Extremely poor
Angle of repose 8
Angle of repose is the maximum angle that can be obtained between the
freestanding surface of a powder heap and the horizontal plane.
Procedure:
It was determined using funnel method. The height of the funnel was
adjusted in such a way that the tip of the funnel just touches the heap of the blends.
Accurately weighed blend is allowed to pass through the funnel freely on to the
surface. The height and diameter of the powder cone was measured and angle of
repose was calculated using the following equation.
Ө = tan-1 (h/r)
Where, h= Height of pile
r= Radius of pile
Ө= Angle of repose
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Table No.5 Standard range of Angle of Repose.
Angle of repose Type of flow
25 – 30 Excellent
31 – 35 Good
36 – 40 Fair
41 – 45 Passable
46 – 55 Poor
56 – 65 Very poor
Above 66 Extremely poor
DRUG EXCIPIENT COMPATABILITY STUDY BY FTIR
SPECTROSCOPY
The FTIR spectra of pure mosapride citrate, mosapride citrate with HPMC
K4M, HPMC K15M and mosapride citrate with HPMC K4M, HPMC K15M,
Lactose, Magnesium stearate, Talc, Aerosil were analyzed for compatibility study.
Procedure:
Drug and excipients were analysed by infra red spectral studies by using
potassium bromide pellet technique. In this method, the drug and potassium bromide
were mixed at the ratio of 1:100. Then these mixtures were pressed in to a pellet.
The FTIR spectra were recorded using potassium bromide pellet method. Spectra
were recorded for pure drug, pure excipients and drug with excipients (tablet). The
instrument was operated under dry air purge and the scans were collected at
scanning speed 2mm/sec with resolution of 4cm-1 over the region 4000-400cm-1.
The scans were evaluated for the presence of principle of peaks of drug, shifting and
masking of drug peaks and appearance of new peaks due to polymer interaction. The
FT-IR spectra of pure Mosapride citrate, are shown in Fig. no-6.
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PREPARATION OF STANDARD CALIBRATION CURVE OF
MOSAPRIDE CITRATE.
Method:
100 mg of mosapride citrate was accurately weighed and transferred into 100
ml volumetric flask. It was dissolved and diluted to volume with purified water to
give stock solution containing 1000µg/ml.
The standard stock solution was then serially diluted with purified water
to get 10ug/ml of mosapride citrate. The λmax was found to be 274 nm using UV
Spectrophotometer. The absorbance values were plotted against concentration
(µg/ml).
FORMULATION DEVELOPMENT OF MOSAPRIDE CITRATE.
Step 1: Weigh the raw materials as per ORML, check control number and record
them.
Step 2: Sifting
Check the integrity of the sieves being used for sifter as per SOP  & first sift
the material dry mixing and then shift material required for dry lubrication as per the
specified sieve for each material.
Table No.6 Materials used for Dry granulation
Materials Actual Quantity
(gm/1000 tablets)
Sieve no
Materials for dry mixing
Mosapride Citrate 10.77 24#
Lactose IP/BP 37.05 24#
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Step 3: Dry Mixing
Blend of Mosapride Citrate with Polymer (HPMC) & lactose mix slowly in
polybag for 15 minutes.  Add half quantity of lubricants & reblend for 5-6 minutes.
Now blend is ready for slug formation.
Step 4: Slugging
Slugging is a method of subjecting a material to increased compression time.
When the initial blend of powders is forced into the dies of a large-capacity tablet
press and is compacted by means of flat-faced punches the compacted masses are
called slugs, and the process is referred to as slugging9. Clean & operate the M/C as
per S.C.P. & S.O.P for Slugging.
Parameters for Slugging:
Punch size 16 mm
Average Weight 900 mg/slug
Hardness NLT 10 Kg/cm2
Step 5: Deslugging
HPMC K4M 20.00 24#
HPMCK15M 25.00 24#
Talcum 0.50 40#
Magnesium Stearate IP/BP 0.50 40#
Aerosil IP/USP 0.10 40#
Materials for dry lubrication
Mosapride Citrate 4.23 24#
Talcum 0.50 40#
Magnesium Stearate IP/BP 0.50 40#
Aerosil IP/USP 0.10 40#
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Deslug the above slug, and screen it through 2 mm screen slowly.  Pass the
final granules through #30.
Step 6: Dry Lubrication
Mix final granules & remaining mosapride citrate slowly in polybag for 15
minutes.  Add remaining half quantity of lubricants slowly for 10 minutes. Record
the total weight of granules.  Now blend is ready for compression.
Step 7: Compression
Clean & operate the machine as per S.C.P. ensure blend release before taking
for compression.  Check batch details on the label & total weight of granules.
Parameters for compression
1.Punch UP: Plain SC, LP: Plain SC.
2.Dimensions 6.00 mm
3.Diameter 6.00 mm ( 0.05)
4.Theoretical Weight to Tablet 94mg / Tab
5.Weight of two Tablets 188mg (2%)
6.Weight variation (of actual average weight)  7.5%
7.Hardness of Tablet NLT 4.0 Kg/cm2
8.Friability NMT 1.0%
9.Thickness 3.0 ( 0.2) mm
10.Appearance of tablet. White to off-white, biconvex.
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Formulation variables for mosapride citrate matrix tablets.
Table No.7. Formulation ingredients.
PHYSICOCHEMICAL EVALUATION OF TABLET
Post compression parameters:
 Shape of tablet:
The compressed tablets were examined under the magnifying lens for the
shape of tablet.
 Uniformity of weight13:
The USP weight variation test was carried out by weighing 20 tablets
individually, calculating the average weight, comparing the individual tablet
weight to average weight. The tablet meet USP test if no tablet differs by more
than two times of percentage deviation.
Ingredients F1(mg)
F2
(mg)
F3
(mg)
F4
(mg)
F5
(mg)
F6
(mg)
F7
(mg)
F8
(mg)
F9
(mg)
Mosapride
citrate
15 15 15 15 15 15 15 15 15
HPMCK4M 10 15 - 10 15 18 16 20 20
HPMC K15 M - - 10 10 10 10 15 20 25
Lactose 73 68 73 62 58 55 52 43 38
Talcum 1 1 1 1 1 1 1 1 1
Magnesium
Stearate
1 1 1 1 1 1 1 1 1
Colloidal silicon
dioxide(Aerosil)
0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
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Table No.8 Standard range of weight of tablets.
Sl.no Average weight of
tablets (mg)
Minimumm
percentage
difference allowed
1 130 or less 10
2 130-324 7.5
3 More than 324 5
 Tablet thickness:
Thickness and diameter were measured using a calibrated dial caliper. Three
tablets of each formulation were taken randomly and thickness was measured
individually.
 Hardness test:
Hardness of the tablet was determined by using the Monsanto hardness tester.
The tester consists of a barrel containing a compressible spring held between two
plungers. The lower plunger is placed in contact with the tablet, and a zero reading
is taken. The upper plunger is then forced against a spring by turning a threaded bolt
until the tablet fractures. As the spring is compressed, a pointer rides along a gauge
in the barrel to indicate the force. The force of fracture is recorded, and the zero
force reading is deducted from it9. The hardness was measured in terms of Kg/cm2
 Friability test:
The most popular and commercially available friability apparatus is the
Roche Friabilator, in which approximately 6g (wo) of dedusted tablets are subjected
to 100 free falls i.e the apparatus revolves at 25rpm dropping the tablets through a
distance of 6 inches in a rotating drum and are then reweighed (w). the friability,f, is
given by:
f= 100. (1-wo/w)
Values of f from 0.8 to 1.0% are regarded as the upper limit of acceptability9.
Chapter-7 Methodology
Department of Pharmaceutics 64 J.K.K. Nattraja College of Pharmacy
IN VITRO DRUG RELEASE STUDY
DISSOLUTION 14, 72
Medium - Acetate buffer pH – 4.0
Apparatus - USP (Type II) paddle type.
Medium volume - 900.0 ml
Speed - 100 rpm
Temperature - 37°C [ 0.5°C]
Wavelength - 274 nm
Sample Withdrawal - At the end of 1st, 4th, 7th, 12th, 16th and 24th hours
Sample volume - 5 ml
Procedure:
Tablets of all preliminary batches were subjected to dissolution rate studies. In
vitro dissolution were carried out on dissolution apparatus (model) to determined the
drug release from various formulations.1000ml of acetate buffer was placed in
vessel and the USP apparatus –II (Paddle Method) was assembled. The medium was
allowed to equilibrate to temp of 37°c + 0.5°c. Studies were carried out in 900 ml of
acetate buffer ph4 upto 24hrs at 100 rpm. The dosage form was allowed to sink to
the bottom of the flask before stirring. dosage forms may have a small loose piece of
nonreactive material such as not more than few turns of wire helix attached to
prevent them from floating. The apparatus was operated for 24 hours and then the
medium was taken and process was continued from 0 to 24 hrs at 100 rpm. At
definite time intervals of 5 ml of the receptors fluid was withdrawn, filtered and
again 5ml receptor fluid was replaced.  Suitable dilutions were done with receptor
fluid and analyzed by spectrophotometrically at 274 nm using UV-
spectrophotometer.
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Standard Dissolution Profile:
Table No.9 Standard dissolution profile.
DATA ANALYSIS
To analyze the mechanism of release and release rate kinetics of the dosage
form, the data obtained were fitted into Zero order, First order, Higuchi matrix,
Korsmeyer and Peppas and Hixson Crowell model using PSP-DISSO – v2 software.
Based on the r-value, the best-fit model was selected.
Zero order kinetics:
Drug dissolution from pharmaceutical dosage forms that do not disaggregate
and release the drug slowly, assuming that the area does not change and no
equilibrium conditions are obtained can be represented by the following equation,
Q t = Q o + K o t…………………………….. (8.11)
Where,
Q t = amount of drug dissolved in time t.
Q o = initial amount of the drug in the solution and
Dissolution Sustained release
profile
After 1st hour NMT – 30%
After 4th hour 30 -50%
After 7th hour 50 – 65%
After 12th hour 70-75%
After 16th hour 75-85%
After 24th hour NLT 90%
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K o = zero order release constant.
First order kinetics:
To study the first order release rate kinetics, the release rate data were fitted to
the following equation,
Log Qt= log Qo+ K1t/2.303……………………………….. (8.12)
Where,
Qt= the amount of drug released in time t,
Qo= the initial amount of drug in the solution
K1 = the first order release constant.
Higuchi model:
Higuchi developed several theoretical models to study the release of water
soluble and low soluble drugs incorporated in semisolids and/or solid matrices.
Mathematical expressions were obtained for drug particles dispersed in a uniform
matrix behaving as the diffusion media. And the equation is,
Qt= KH ·t1/2…………………………………….. (8.13)
Where,
Qt= amount of drug released in time t,
KH = Higuchi dissolution constant.
Korsmeyer and Peppas release model:
To study this model the release rate data are fitted to the following equation,
Mt / M ¥ = K · t n……………………………………… (8.14)
Where,
Mt / M ¥ = the fraction of drug release,
K = the release constant,
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T = the release time,
N = the diffusional coefficient for the drug release that is
dependent on the shape of the matrix dosage form.
Table No.10 Release Kinetics
DIFFUSION
EXPONENT
Release Exponent(n)
OVERALL SOLUTE DIFFUSION
MECHANISM
Drug Transport Mechanism
0.45
0.5
Fickian Diffusion
SLAB/CYLINDER
0.45<n<0.89
0.5<n<1.0
Anomalous (Non Fickian)Transport
SLAB/CYLINDER
0.89
1.0
Case II
SLAB/CYLINDER
n>0.89
n>1.0
Super Case II Transport
SLAB/CYLINDER
STABILITY STUDY
Stability of a pharmaceutical preparation can be defined as ‘the capability of
a particular formulation in a specific container/closure system to remain within its
physical, chemical, microbiological, therapeutic and toxicological specifications
throughout its shelf-life.’ The purpose of stability testing is to provide evidence on
how the quality of drug substance or drug product varies with time under influence
of a variety of environmental factors such as temperature, humidity and light, and
enables recommended storage conditions, re-test periods and shelf-lives to be
established.
An ethical drug manufacturer is committed to provide to his consumers drug
products, which are efficacious and safe. This can be ensured only by instituting a
sound programmed to study the stability of a product during its various phases of
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development and to arrive at the proper storage conditions and the expiry period
under those conditions. This is a requirement in most of the countries and is
stipulated by the regulatory agencies of those countries. These studies would very
quickly identify the need, if any, to stabilize the active substance or the formulation,
and save invaluable time and effort from being spend on an unmarketable
formulation. With the recent trend towards globalization of manufacturing
operation, it is imperative that the final product be sufficiently rugged for marketing
worldwide under various climatic conditions including tropical, subtropical and
temperate.
Long term testing: 25ºC±2 ºC/60% RH±5%RH for 12 months.
Accelerated testing: 40ºC±2 ºC/75% RH±5%RH for 6 months.
Procedure:
In the present study, stability studies were carried out at 40ºC and 75% RH for
a specific time period upto 3 months for selected formulations. For stability study,
the tablets were sealed in aluminium packaging coated inside with polyethylene.
These sample containers were placed in dessicator maintained at 75% RH.
Note: Saturated solution of sodium chloride at 400 ºC yields a 75% relative
humidity.
Evaluation of samples:
The samples were analyzed for the following parameters:
1. Physical evaluation:
Appearance: The samples were checked for any change in colour at every
week.
Hardness: The samples were tested for hardness at every week.
2. Chemical evaluation:
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Drug release: The samples were subjected to drug release studies.
ANALYSIS OF REFERENCE / INNOVATOR PRODUCT
With the help of analysis of the innovator product we will be able to compare the
results obtained of our formulated product.
Analysis of the innovator product was carried out for various physical
parameters and In-vitro dissolution profile.
Table No.11 Reference product physical characterization
GENERIC
NAME
BRAND
NAME
MANUFACTURED
AND MARKETED
BY
STRENGTH DOSAGE
FORM
THICKNESS
Mosapride
Sustained
Release
Tablets
MOZA
SR
Intas Pharmaceuticals 5mg,10mg Sustained
release tablet
3mm
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RESULTS AND DISCUSSION
PREFORMULATION STUDIES
Precompression parameters
Table No.12. Physical parameters of granules before dry granulation (slugging)
Physical parameters of granules after dry granulation (slugging)
For the granules of all the formulated batches, the results of the pre-
compression parameters were found within their respective limits after carrying out
dry granulation technique. The various parameters such as bulk density, tapped
density, compressibility index, hausner’s ratio and angle of repose were re-tested.
Compressibility index was found within the limits 5-40. Hausner’s ratio was
less than 1.25 for all batches indicating good flow properties. The angle of repose
was also found to be in the range of 25° to 30°, thus indicating that the flow
properties were good.
Physical
Properties
F1 F2 F3 F4 F5 F6 F7 F8 F9
Bulk
Density(gm/ml)
0.434 0.435 0.433 0.431 0.435 0.439 0.428 0.422 0.438
Tapped
Density(gm/ml)
0.625 0.626 0.631 0.628 0.630 0.634 0.623 0.615 0.632
Compressibility
Index
31.45 32.60 31.02 31.36 30.95 30.75 31.30 31.38 30.69
Hausner’s
Ratio(H.R.)
1.39 1.40 1.44 1.45 1.448 1.444 1.46 1.467 1.452
Angle of Repose 34°33" 34°18" 32°64" 33°75" 32°42" 32°05" 31°47" 32°55" 33°32"
Observation Poor
flow
Poor
flow
Poor
flow
Poor
flow
Poor
flow
Poor
flow
Poor
flow
Poor
flow
Poor
flow
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Table No.13 Physical parameters of granules after dry granulation
Fig.6 FTIR Spectra of mosapride citrate
Physical
Properties
F1 F2 F3 F4 F5 F6 F7 F8 F9
Bulk
Density(gm/ml)
0.437 0.439 0.436 0.438 0.435 0.440 0.426 0.429 0.443
Tapped
Density(gm/ml)
0.502 0.509 0.513 0.510 0.516 0.521 0.511 0.523 0.512
Compressibility
Index**
15.35 15.22 14.29 14.15 15.69 15.54 16.63 17.01 15.10
Hausner’s
Ratio(H.R.)
1.17 1.15 1.18 1.16 1.18 1.18 1.19 1.21 1.18
Angle of Repose 24°12" 23°21" 23°44" 24°32" 24°51" 25°32 " 23°49" 26°60" 25°11 "
Observation good
flow
good
flow
good
flow
good
flow
good
flow
good
flow
good
flow
good
flow
good
flow
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Fig.7 FTIR Spectra of mosapride citrate with HPMC K4M and HPMC K15M
Fig.8 FTIR Spectra of Mosapride citrate with two different grades of
hydroxypropyl methyl cellulose polymer (HPMC K4M and HPMC K15M) and
other excipients of formulations.
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Table No.14 Interpretation of FTIR Spectra15,16.
In FTIR study the characteristic peak due to pure mosapride has appeared in
the spectra of formulation without any makeable changes in the position. This
confirms the identity and compatibility among the drug mosapride citrate, the
polymers used HPMC K4M, HPMC K15M and other excipients of the formulation.
Standard Curve of Mosapride citrate in Acetate Buffer pH-4.0
The calibration curve of mosapride citrate was prepared in acetate buffer
ph4.0 following table no-15, shows the absorbance at ƛmax 274 nm and fig no-9
shows the calibration curve with regression coefficient 0.994, and the y intercept
0.022.
Table No.15 Standard Curve of Mosapradi citrate.
Concentration
In µg/ml
Absorbance at 274 nm in
Acetate buffer  pH- 4.0
0 0 ± 0
2 0.055  ± 0.0019
4 0.09  ±0.0016
6 0.137  ± 0.0021
8 0.172  ± 0.0013
Sr.No Functional groups presents in
mosapride citrate.
Standard
FTIR range
Observed Peak
1 C=O (in ketone) 1705-1725 1724.11
2 C-N (vibrations) 1000-1400 1400.20,1434.94,1450.37
3 C-H 700-850 607,669,700,715,746,798
4 C-Cl 800-600 700.11
5 C-F 1000-1400 1201.57
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10 0.202  ±0.0018
12 0.271  ±0.0013
14 0.325  ±0.0011
16 0.358  ±0.0019
18 0.428  ±0.0011
20 0.457  ±0.0014
Fig.9 Standard Curve  of Mosapride citrate in Acetate Buffer pH-4.0
EVALUATION OF TABLETS
Physical Parameters of Prepared Tablets-post compression parameters
The tablets from each batch of factorial design were evaluated for uniformity
of weight, thickness, hardness, friability and the results were reported in table no --.
The tablets showed good weight uniformity as indicated by the low value of
Relative Standard Deviation (RSD<1%). The tablet thickness were found in the
range of 3.90±0.01mm to 4.00±0.01mm. the tablet hardness varied from—to --. The
tables pass the friability test, as all the batches were within the pharmacopoeial limit.
(F<1%).
y = 0.0228x
R² = 0.9946
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
0.5
0 10 20 30
Ab
sor
ba
nce
Concentration in µg/ml
Standard Curve  Of Mosapride citrate in Acetate
Buffer pH-4.0
Linear (Abs)
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Table No. 16 Post compression parameters of mosapride citrate.
Formulations
Uniformity in
weight (mg)
Thickness
variation (mm)
Hardness
(kg/cm2)
Friability
(%)
F1 98.4 3.16 5.20 0.103
F2 98.90 3.21 4.40 0.210
F3 99.02 3.15 4.60 0.141
F4 99.97 3.12 5.30 0.158
F5 99.89 3.20 4.60 0.21
F6 99.74 3.08 4.70 0.265
F7 99.37 3.22 5.30 0.106
F8 98.59 3.15 4.90 0.150
F9 99.98 3.13 5.20 0.160
Time
(hrs)
Average percentage drug release
F1 F2 F3 F4 F5 F6 F7 F8 F9
0 0 0 0 0 0 0 0 0 0
1 40.07 41.89 38.99 45.54 42.01 35.00 30.82 25.06 24.3
4 65.0 60.04 59.37 78.53 63.0 53.23 47.11 44.11 41.9
7 96.22 89.93 85.0 97.0 86.72 79.09 72.40 66.29 58.20
12 -- 97.02 98.89 - 98.58 97.66 84.21 79.56 74.10
16 -- -- -- - - - 97.0 98.01 83.50
24 -- -- -- - - - - - 98.6
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Table No.17 Dissolution Profiles of Formulation F1-F9.
Fig.10 Comparative dissolution profiles of F1-F9
Table No.18 Kinetic studies of optimum formulation F9
S. No Time
in
hours
Log
time
Square
root of
time
Cumulative
percentage
drug
release
Cumulative
percentage
drug
remain
Log
cumulative
percentage
drug
release
Log
cumulative
percentage
drug remain
1 0 - 0 0 100 - 2
2 1 0 1 24.3 75.7 1.385 1.879
3 4 0.602 2 41.9 58.1 1.622 1.764
4 7 0.845 2.645 58.20 41.8 1.764 1.621
5 12 1.079 3.464 74.10 25.9 1.869 1.413
6 16 1.204 4 83.50 16.5 1.921 1.217
7 24 1.380 4.898 98.6 1.4 1.993 0.146
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Fig.11 Zero Order Drug Release Kinetics of F9.
Fig.12 First Order Drug Release Kinetics of F9.
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Fig.13 Higuchi Model Of Drug Release Kinetics For F9
Fig.14 Korsmeyer-Peppas Release Kinetics of F9.
Table No.19 Kinetic values obtained from F9 plot formulation of Mosapride
citrate
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Formulation Zero
order R2
First
order R2
Higuchi
R2
Korsmeyer –
Peppas R2
N Mechanism of
drug release
F9 0.943 0.910 0.941 0.926 0.724 Zero order Non
Fickian diffusion
Mechanism of drug release
In order to understand the complex mechanism of drug release from the
matrix system, the in vitro release rate were fitted to korsmeyer peppas model and
interpretation of release exponent value (n) enlighten in understanding the release
mechanism from the dosage form. The release exponent value (n) thus obtained was
0.724. the F9 formulation exhibited anomalous (non fickian) diffusion mechanism.
The drug release was diffusion controlled as plot of Higuchi’s model was found to
be linear.
These formulations also showed higher r2value of zero order release kinetics
thereby indicating that the release of drug from the matrix system were both by
diffusion and erosion.
Stability studies as per ICH guidelines
The optimized formulation F9 of Mosapride citrate sustained release matrix
tablets were evaluated for stability studies at 400C ±20C/75 % RH±5% for 90 days.
The product was evaluated for appearance and hardness for every 10 days. Drug
release studies were conducted as per planned schedule. The stability details / results
are presented as below.
Storage Condition- 400C / 75 % RH
Pack- HDPE Container
Storage Period- 1 month, 2 months and 3 months.
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Table No. 20:  Stability data
Table No. 21:  Stability data
Fig.No-15 Stability plot of F9 formulation
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Stability plot of F9 formulation
1st month
2nd month
3rd month
Duration Hardness(kg/cm) Friability (%)
After one month 5.20 0.160
After two months 5.20 0.160
After three months 5.19 0.161
Time in
hours
Cumulative percentage drug release
1st month 2nd month 3rd month
0 0 0 0
1 24.1 24.0 23.98
4 41.8 41.6 41.52
7 58.2 58 57.97
12 74 73.8 73.65
16 83.3 83 82.95
24 98.4 98.3 97.82
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9. SUMMARY AND CONCLUSION
The present study was carried out to develop sustained release matrix tablets of
mosapride citrate. Matrix tablets of mosapride citrate with two different viscosity
grades of hydroxypropyl methylcellulose were prepared by dry granulation and
direct compression method and evaluated.
The FTIR study was carried out to know the compatibility of the excipients
with mosapride citrate dihydrate, the active constituent of the formulation. The FTIR
spectrum of pure mosapride citrate, mixture of mosapride citrate with, HPMC K4M,
HPMC K15M polymers and mixture of mosapride citrate, HPMC K15M, HPMC
K4M with Lactose, talc, magnesium stearate, aerosil were analyzed for
compatibility study. The study of FTIR spectrum confirms that mosapride citrate
and excipients used in the formulation are compatible with each other.
The Sustained release Matrix tablets of mosapride citrate dihydrate were
prepared by Dry granulation / roller compaction technique and Direct Compression
Method. The angle of repose of the granules after slugging (dry granulation) was
found to have 24° to 26°. The matrix tablets were compressed by applying optimum
force of compression and the hardness of tablets was found to be in the range of 4.6
to 5.3kg/cm2.
The flow property of the granules was good after slugging that was
confirmed by the determination of angle of repose which indicates better uniformity
of weight. Good hardness of the matrix tablets with less standard deviation indicated
retardation in the release as observed in dissolution profile.
On performing the friability for all the formulations the % weight loss falls
between the range 0.26% and 0.60% indicates that it falls within the limit showing
good compressibility and non defective tabletting.
In first attempt of study, matrix tablets were prepared by using
hydroxypropyl methylcellulose (HPMC) of lower viscosity alone i.e.HPMC K4M
(10%). This formulation (i.e. F1) failed to sustain the drug release for extended
period of time and all most all the drug got released in 7th hour. For sustaining the
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drug release up to 24th hour the percentage of HPMC K4M in F2 was increased
(15%) but the formulation did not sustain the drug release more than 12th hour. It
clearly indicates that the lower viscosity grade of hydroxypropyl methylcellulose
(HPMC K4M) is able to sustain the drug release up 12th hour and for sustaining the
drug release for extended period up to 24th hour, percentage of higher viscosity
grade of hydroxypropyl methylcellulose (HPMC K15M) must be used.
In formulation F3, HPMC K15M was used alone (i.e.10%) and the tablets
were evaluated for in vitro dissolution study. The formulation failed to sustain the
release up to extended period of time. In Formulation F4 ( HPMC K4M 10%, and
HPMC K15M 10%) sustained the drug release up to 7th hour, so in formulation F5
the percentage of HPMC K15 was kept constant and the percentage of HPMC K4
was increased, this formulation released the drug in 12th hour. In formulation F6 the
percentage of HPMC K4M was further increased and the percentage of HPMC
K15M was kept constant. This formulation also failed to sustain the drug release. F7
slowly released the drug, up to 16th hour. The total drug release from formulation F8
was (98.01%) but it also failed to sustain the release up to 24 hour.
In formulation F9, percentage of HPMC K15M was increased from 20% (in
F8) to 25mg (in F9) while the percentage of HPMC K4M was kept constant up to 20
and tablets of formulation F9 were evaluated for in vitro dissolution study. The
matrix tablets of formulation F9 released the drug slowly as per standard dissolution
profile up to 24th hour and total drug release from matrix tablet of formulation F9 at
the end of 24th hour was 98.01%.
Hence the above study demonstrated that combination of HPMC K4M and
HPMC K15M can be used to formulate sustained release matrix tablets of mosapride
citrate. This can sustain the drug release up to 24 hours as per standard dissolution
profile. This can be expected to reduce the frequency of administration and decrease
the dose – dependent side effects associated with repeated administration of
conventional mosapride citrate dihydrate tablets. The cumulative drug release of
innovators brand (MOZA SR, Intas Pharmaceuticals) of sustained release tablet of
mosapride citrate were compared for in vitro dissolution study. The formulation F9
matrix tablet releases the drug appropriately in comparison of innovators brand. The
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cumulative drug release at the end of 24th hour from formulation F9 (98.01%) and
the cumulative drug release at the end of 24th hour from innovators brand was
(97.30%).
The in vitro drug release result indicates that formulation F9 released more
drug than innovators brand and hence more drug is available at the absorption site
from formulation F9 as compared to innovators brand, hence the formulation F9 has
better bioavailability than innovators brand of mosapride citrate sustained release
matrix tablet and also the sustained release matrix tablet was found to be beneficial
in terms of reduction in frequency of administration.
The formulation F9 best suited with zero order release kinetics (corr.
coefficient =0.943) than the first order release kinetics (corr. Coefficient = 0.910).
The formulation F9 follows Higuchi model of drug release kinetics (corr.
coefficient=0.41).
The Koresmyer peppas drug release kinetics showed correlation coefficient
(0.926) and release exponent (n) 0.724 which indicates that the drug release
mechanism is non-fickanian diffusion.
Hence it can be concluded that once daily sustain release matrix tablet of
mosapride citrate having short half life, was found to exert a satisfactory sustained
release profile which may provide an improved bioavailability, increased therapeutic
efficacy and patient compliance.
